Phosphorylation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NFATp	B-protein
inhibits	O
its	O
DNA	O
binding	O
activity	O
in	O
cyclosporin	B-cell_line
A-treated	I-cell_line
human	I-cell_line
B	I-cell_line
and	O
T	B-cell_type
cells	I-cell_type
.	O

Cyclosporin	O
A	O
(	O
CsA	O
)	O
exerts	O
its	O
immunosuppressive	O
effect	O
by	O
inhibiting	O
the	O
activity	O
of	O
nuclear	B-protein
factor	I-protein
of	O
activated	O
T	B-cell_type
cells	I-cell_type
(	O
NFAT	B-protein
)	O
,	O
thus	O
preventing	O
transcriptional	O
induction	O
of	O
several	O
cytokine	O
genes	O
.	O

This	O
effect	O
is	O
thought	O
to	O
be	O
largely	O
mediated	O
through	O
inactivation	O
of	O
the	O
phosphatase	O
calcineurin	B-protein
,	O
which	O
in	O
turn	O
inhibits	O
translocation	O
of	O
an	O
NFAT	B-protein
component	O
to	O
the	O
nucleus	O
.	O

Here	O
we	O
report	O
that	O
CsA	O
treatment	O
of	O
Raji	B-cell_line
B	I-cell_line
and	O
Jurkat	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
yields	O
a	O
phosphorylated	O
form	O
of	O
NFATp	B-protein
that	O
is	O
inhibited	O
in	O
DNA-binding	O
and	O
in	O
its	O
ability	O
to	O
form	O
an	O
NFAT	B-protein
complex	I-protein
with	O
Fos	B-protein
and	O
Jun	B-protein
.	O

Immunoblot	O
analyses	O
and	O
metabolic	O
labeling	O
with	O
[	O
32P	O
]	O
orthophosphate	O
show	O
that	O
CsA	O
alters	O
NFATp	B-protein
migration	O
on	O
SDS-polyacrylamide	O
gel	O
electrophoresis	O
by	O
increasing	O
its	O
phosphorylation	O
level	O
without	O
affecting	O
subcellular	O
distribution	O
.	O

Dephosphorylation	O
by	O
in	O
vitro	O
treatment	O
with	O
calcineurin	B-protein
or	O
alkaline	B-protein
phosphatase	I-protein
restores	O
NFATp	B-protein
DNA	O
binding	O
activity	O
and	O
its	O
ability	O
to	O
reconstitute	O
an	O
NFAT	B-protein
complex	I-protein
with	O
Fos	B-protein
and	O
Jun	B-protein
proteins	O
.	O

These	O
data	O
point	O
to	O
a	O
new	O
mechanism	O
for	O
CsA-sensitive	O
regulation	O
of	O
NFATp	B-protein
in	O
which	O
dephosphorylation	O
is	O
critical	O
for	O
DNA	O
binding	O
.	O

THE	NULL
JOURNAL	NULL
or	NULL
BIOLOGICAL	NULL
CHEMISTRY	NULL
.	NULL

©	NULL
1995	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Biochemistry	NULL
and	NULL
Molecular	NULL
Biology	NULL
,	NULL
Inc.	NULL
Vol	NULL
.	NULL

270	NULL
,	NULL
No	NULL
.	NULL

35	NULL
,	NULL
Issue	NULL
of	NULL
September	NULL
1	NULL
,	NULL
pp	NULL
.	NULL

20653-20659	NULL
,	NULL
1995	NULL
Printed	NULL
in	NULL
U.S.A.	NULL
Phosphorylation	NULL
of	NULL
the	NULL
Transcription	NULL
Factor	NULL
NFATp	NULL
Inhibits	NULL
Its	NULL
DNA	NULL
Binding	NULL
Activity	NULL
in	NULL
Cyclosporin	NULL
A-treated	NULL
Human	NULL
B	NULL
and	NULL
T	NULL
Cells*	NULL
(	NULL
Received	NULL
for	NULL
publication	NULL
,	NULL
April	NULL
4	NULL
,	NULL
1995	NULL
,	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
,	NULL
June	NULL
12	NULL
,	NULL
1995	NULL
)	NULL
Jungchan	NULL
Park	NULL
}	NULL
,	NULL
Nabeel	NULL
R.	NULL
Yaseent	NULL
,	NULL
Patrick	NULL
G.	NULL
Hogan§	NULL
,	NULL
Anjana	NULL
Raot|**	NULL
,	NULL
and	NULL
Surendra	NULL
Sharmai	NULL
#	NULL
#	NULL
}	NULL
From	NULL
the	NULL
{	NULL
Section	NULL
of	NULL
Experimental	NULL
Pathology	NULL
,	NULL
Department	NULL
of	NULL
Pathology	NULL
,	NULL
Roger	NULL
Williams	NULL
Medical	NULL
Center-Brown	NULL
University	NULL
,	NULL
Providence	NULL
,	NULL
Rhode	NULL
Island	NULL
02908	NULL
,	NULL
the	NULL
§Department	NULL
of	NULL
Neurobiology	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
the	NULL
Division	NULL
of	NULL
Cellular	NULL
and	NULL
Molecular	NULL
Biology	NULL
,	NULL
Dana	NULL
Farber	NULL
Cancer	NULL
Institute	NULL
,	NULL
and	NULL
the	NULL
Department	NULL
of	NULL
Pathology	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
Boston	NULL
,	NULL
Massachusetts	NULL
02115	NULL
Cyclosporin	NULL
A	NULL
(	NULL
CsA	NULL
)	NULL
exerts	NULL
its	NULL
immunosuppressive	NULL
effect	NULL
by	NULL
inhibiting	NULL
the	NULL
activity	NULL
of	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
NFAT	NULL
)	NULL
,	NULL
thus	NULL
preventing	NULL
transcriptional	NULL
induction	NULL
of	NULL
several	NULL
cytokine	NULL
genes	NULL
.	NULL

This	NULL
effect	NULL
is	NULL
thought	NULL
to	NULL
be	NULL
largely	NULL
mediated	NULL
through	NULL
inactivation	NULL
of	NULL
the	NULL
phosphatase	NULL
calcineurin	NULL
,	NULL
which	NULL
in	NULL
turn	NULL
inhibits	NULL
translocation	NULL
of	NULL
an	NULL
NFAT	NULL
component	NULL
to	NULL
the	NULL
nucleus	NULL
.	NULL

Here	NULL
we	NULL
report	NULL
that	NULL
CsA	NULL
treatment	NULL
of	NULL
Raji	NULL
B	NULL
and	NULL
Jurkat	NULL
T	NULL
cell	NULL
lines	NULL
yields	NULL
a	NULL
phosphorylated	NULL
form	NULL
of	NULL
NFATp	NULL
that	NULL
is	NULL
inhibited	NULL
in	NULL
DNA-binding	NULL
and	NULL
in	NULL
its	NULL
ability	NULL
to	NULL
form	NULL
an	NULL
NFAT	NULL
complex	NULL
with	NULL
Fos	NULL
and	NULL
Jun	NULL
.	NULL

Immunoblot	NULL
analyses	NULL
and	NULL
metabolic	NULL
labeling	NULL
with	NULL
show	NULL
that	NULL
CsA	NULL
alters	NULL
NFATp	NULL
migration	NULL
on	NULL
SDS-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
by	NULL
increasing	NULL
its	NULL
phosphorylation	NULL
level	NULL
without	NULL
affecting	NULL
subcellular	NULL
distribution	NULL
.	NULL

Dephosphorylation	NULL
by	NULL
in	NULL
vitro	NULL
treatment	NULL
with	NULL
calcineurin	NULL
or	NULL
alkaline	NULL
phosphatase	NULL
restores	NULL
NFATp	NULL
DNA	NULL
binding	NULL
activity	NULL
and	NULL
its	NULL
ability	NULL
to	NULL
reconstitute	NULL
an	NULL
NFAT	NULL
complex	NULL
with	NULL
Fos	NULL
and	NULL
Jun	NULL
proteins	NULL
.	NULL

These	NULL
data	NULL
point	NULL
to	NULL
a	NULL
new	NULL
mechanism	NULL
for	NULL
CsA-sensitive	NULL
regulation	NULL
of	NULL
NFATp	NULL
in	NULL
which	NULL
dephosphorylation	NULL
is	NULL
critical	NULL
for	NULL
DNA	NULL
binding	NULL
.	NULL

The	NULL
immunosuppressive	NULL
drugs	NULL
cyclosporin	NULL
A	NULL
(	NULL
CsA	NULL
)	NULL
and	NULL
FK-506	NULL
repress	NULL
an	NULL
early	NULL
event	NULL
in	NULL
T	NULL
cell	NULL
activation	NULL
by	NULL
inhibiting	NULL
a	NULL
step	NULL
(	NULL
s	NULL
)	NULL
in	NULL
intracellular	NULL
calcium	NULL
signaling	NULL
,	NULL
thus	NULL
preventing	NULL
the	NULL
transcription	NULL
of	NULL
several	NULL
cytokine	NULL
genes	NULL
including	NULL
interleukin	NULL
(	NULL
IL	NULL
)	NULL
-2	NULL
,	NULL
IL-3	NULL
,	NULL
IL-4	NULL
,	NULL
granulocyte/macrophage	NULL
colony-stimulating	NULL
factor	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor-	NULL
«	NULL
,	NULL
and	NULL
other	NULL
molecules	NULL
that	NULL
play	NULL
a	NULL
major	NULL
role	NULL
in	NULL
coordinating	NULL
the	NULL
immune	NULL
response	NULL
(	NULL
for	NULL
review	NULL
,	NULL
see	NULL
Sigal	NULL
and	NULL
Dumont	NULL
(	NULL
1992	NULL
)	NULL
,	NULL
Schreiber	NULL
and	NULL
Crabtree	NULL
(	NULL
1992	NULL
)	NULL
,	NULL
and	NULL
Bierer	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
mechanism	NULL
(	NULL
s	NULL
)	NULL
by	NULL
which	NULL
these	NULL
drugs	NULL
inhibit	NULL
transcription	NULL
of	NULL
a	NULL
discrete	NULL
set	NULL
of	NULL
cytokines	NULL
is	NULL
not	NULL
yet	NULL
well	NULL
defined	NULL
,	NULL
recent	NULL
studies	NULL
have	NULL
implicated	NULL
the	NULL
Ca**/cal-modulin-dependent	NULL
protein	NULL
phosphatase	NULL
,	NULL
calcineurin	NULL
(	NULL
CaN	NULL
)	NULL
,	NULL
as	NULL
*	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Grants	NULL
CA55910	NULL
(	NULL
to	NULL
S.	NULL
S.	NULL
)	NULL
and	NULL
CA42471	NULL
and	NULL
GM46227	NULL
(	NULL
to	NULL
A.	NULL
R.	NULL
)	NULL
,	NULL
and	NULL
by	NULL
grants	NULL
from	NULL
the	NULL
Harvard-Hoffmann	NULL
LaRoche	NULL
collaborative	NULL
research	NULL
agreement	NULL
(	NULL
to	NULL
A.	NULL
R.	NULL
and	NULL
P.	NULL
G.	NULL
H.	NULL
)	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

**	NULL
Supported	NULL
by	NULL
a	NULL
scholar	NULL
award	NULL
form	NULL
the	NULL
Leukemia	NULL
Society	NULL
of	NULL
America	NULL
.	NULL

#	NULL
}	NULL
To	NULL
whom	NULL
correspondence	NULL
and	NULL
reprint	NULL
requests	NULL
should	NULL
be	NULL
ad-dressed	NULL
.	NULL

Tel	NULL
.	NULL

:	NULL
401-456-6565	NULL
;	NULL
Fax	NULL
:	NULL
401-456-6569	NULL
.	NULL
'	NULL

The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
CsA	NULL
,	NULL
cyclosporin	NULL
A	NULL
;	NULL
IL	NULL
,	NULL
interleukin	NULL
;	NULL
PMA	NULL
,	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
;	NULL
PHA	NULL
,	NULL
phytohemagglutinin	NULL
;	NULL
NFAT	NULL
,	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
;	NULL
CaN	NULL
,	NULL
calcineurin	NULL
;	NULL
AP	NULL
,	NULL
calf	NULL
intestinal	NULL
alkaline	NULL
phosphatase	NULL
;	NULL
EMSA	NULL
,	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
;	NULL
USF	NULL
,	NULL
upstream	NULL
stimulatory	NULL
transcription	NULL
factor	NULL
;	NULL
LDH	NULL
,	NULL
H	NULL
subunit	NULL
of	NULL
lactate	NULL
dehydrogenase	NULL
.	NULL

an	NULL
intracellular	NULL
component	NULL
responsible	NULL
for	NULL
regulating	NULL
the	NULL
drug-sensitive	NULL
expression	NULL
of	NULL
at	NULL
least	NULL
the	NULL
IL-2	NULL
,	NULL
tumor	NULL
necrosis	NULL
fac-tor-a	NULL
,	NULL
and	NULL
granulocyte/macrophage	NULL
colony-stimulating	NULL
factor	NULL
genes	NULL
(	NULL
Clipstone	NULL
and	NULL
Crabtree	NULL
,	NULL
1992	NULL
;	NULL
O'Keefe	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
;	NULL
Goldfeld	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Tsuboi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

Nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
NFAT	NULL
)	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
transcription	NULL
of	NULL
these	NULL
cytokines	NULL
and	NULL
may	NULL
be	NULL
a	NULL
major	NULL
target	NULL
of	NULL
the	NULL
activity	NULL
of	NULL
CaN	NULL
and	NULL
the	NULL
immunosuppressive	NULL
drugs	NULL
(	NULL
Emmel	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Granelli-Piperno	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Randak	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Chuypilo	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Cockerill	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
;	NULL
Goldfeld	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Masuda	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Szabo	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Rooney	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
for	NULL
review	NULL
,	NULL
see	NULL
Rao	NULL
(	NULL
1994	NULL
)	NULL
)	NULL
.	NULL

Induction	NULL
of	NULL
NFAT	NULL
parallels	NULL
that	NULL
of	NULL
IL-2	NULL
and	NULL
requires	NULL
protein	NULL
kinase	NULL
C-dependent	NULL
and	NULL
Ca**-dependent	NULL
signaling	NULL
processes	NULL
that	NULL
can	NULL
be	NULL
triggered	NULL
in	NULL
vitro	NULL
by	NULL
the	NULL
combination	NULL
of	NULL
phorbol	NULL
ester	NULL
(	NULL
PMA	NULL
)	NULL
and	NULL
ionomycin	NULL
or	NULL
PMA	NULL
and	NULL
phytohemag-glutinin	NULL
(	NULL
PHA	NULL
)	NULL
(	NULL
Durand	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
;	NULL
Ullman	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Flanagan	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

The	NULL
structural	NULL
complexity	NULL
of	NULL
NFAT	NULL
was	NULL
first	NULL
appreciated	NULL
by	NULL
Flanagan	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
,	NULL
who	NULL
proposed	NULL
a	NULL
two-component	NULL
structure	NULL
consisting	NULL
of	NULL
a	NULL
PMA-inducible	NULL
nuclear	NULL
component	NULL
resistant	NULL
to	NULL
CsA	NULL
and	NULL
FK-506	NULL
and	NULL
a	NULL
T	NULL
cell-specific	NULL
cytosolic	NULL
component	NULL
present	NULL
in	NULL
unstimulated	NULL
T	NULL
cells	NULL
that	NULL
translocated	NULL
to	NULL
the	NULL
nucleus	NULL
upon	NULL
ionomycin	NULL
or	NULL
PHA	NULL
stimulation	NULL
.	NULL

The	NULL
translocation	NULL
of	NULL
the	NULL
cytosolic	NULL
component	NULL
is	NULL
sensitive	NULL
to	NULL
CsA	NULL
and	NULL
FK-506	NULL
,	NULL
indicating	NULL
that	NULL
this	NULL
step	NULL
is	NULL
controlled	NULL
directly	NULL
or	NULL
indirectly	NULL
by	NULL
CaN	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
simplest	NULL
proposal	NULL
to	NULL
account	NULL
for	NULL
activation	NULL
has	NULL
been	NULL
that	NULL
CaN	NULL
``	NULL
activates	NULL
``	NULL
NFAT	NULL
solely	NULL
by	NULL
controlling	NULL
translocation	NULL
of	NULL
the	NULL
cytosolic	NULL
component	NULL
to	NULL
the	NULL
nucleus	NULL
(	NULL
Schreiber	NULL
and	NULL
Crabtree	NULL
,	NULL
1992	NULL
)	NULL
.	NULL

The	NULL
PMA-inducible	NULL
nuclear	NULL
component	NULL
was	NULL
later	NULL
shown	NULL
to	NULL
consist	NULL
of	NULL
ubiquitous	NULL
Fos	NULL
and	NULL
Jun	NULL
family	NULL
proteins	NULL
(	NULL
Jain	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
,	NULL
1993a	NULL
;	NULL
Boise	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Northrop	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Yaseen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
,	NULL
1994	NULL
;	NULL
Jain	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
a	NULL
pre-existing	NULL
component	NULL
of	NULL
NFAT	NULL
(	NULL
NFATp	NULL
)	NULL
(	NULL
for	NULL
review	NULL
,	NULL
see	NULL
Rao	NULL
(	NULL
1994	NULL
)	NULL
)	NULL
was	NULL
purified	NULL
from	NULL
cytoplasmic	NULL
extracts	NULL
of	NULL
a	NULL
murine	NULL
T	NULL
cell	NULL
line	NULL
(	NULL
Jain	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998a	NULL
)	NULL
,	NULL
and	NULL
its	NULL
cDNA	NULL
was	NULL
cloned	NULL
(	NULL
McCaffrey	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993b	NULL
)	NULL
.	NULL

Although	NULL
its	NULL
expression	NULL
is	NULL
not	NULL
restricted	NULL
to	NULL
T	NULL
cells	NULL
,	NULL
its	NULL
biochemical	NULL
characteristics	NULL
are	NULL
very	NULL
similar	NULL
to	NULL
the	NULL
cytosolic	NULL
component	NULL
that	NULL
has	NULL
been	NULL
described	NULL
by	NULL
Flanagan	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
.	NULL

NFATp	NULL
is	NULL
present	NULL
in	NULL
the	NULL
cytoplasm	NULL
of	NULL
unstimulated	NULL
murine	NULL
T	NULL
cells	NULL
,	NULL
it	NULL
translocates	NULL
to	NULL
the	NULL
nucleus	NULL
upon	NULL
Ca**-dependent	NULL
stimulation	NULL
,	NULL
and	NULL
its	NULL
translocation	NULL
is	NULL
blocked	NULL
by	NULL
CsA	NULL
.	NULL

Purified	NULL
NFAT	NULL
p	NULL
is	NULL
able	NULL
to	NULL
directly	NULL
bind	NULL
to	NULL
the	NULL
murine	NULL
IL-2	NULL
NFAT	NULL
motif	NULL
and	NULL
to	NULL
form	NULL
an	NULL
NFAT	NULL
complex	NULL
in	NULL
association	NULL
with	NULL
Fos	NULL
and	NULL
Jun	NULL
proteins	NULL
(	NULL
Jain	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993a	NULL
;	NULL
McCaffrey	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993b	NULL
)	NULL
.	NULL

NFATp	NULL
is	NULL
a	NULL
phosphoprotein	NULL
with	NULL
a	NULL
molecular	NULL
mass	NULL
of	NULL
~120	NULL
kDa	NULL
that	NULL
acts	NULL
as	NULL
an	NULL
in	NULL
vitro	NULL
substrate	NULL
of	NULL
CaN	NULL
(	NULL
Jain	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998a	NULL
;	NULL
McCaffrey	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993a	NULL
)	NULL
,	NULL
supporting	NULL
the	NULL
notion	NULL
that	NULL
NFATp	NULL
is	NULL
a	NULL
potential	NULL
*	NULL
K.	NULL
T.	NULL
Y.	NULL
Shaw	NULL
,	NULL
A.	NULL
M.	NULL
Ho	NULL
,	NULL
A.	NULL
Raghavan	NULL
,	NULL
J.	NULL
Kim	NULL
,	NULL
J.	NULL
Jain	NULL
,	NULL
J	NULL
.	NULL

Park	NULL
,	NULL
S.	NULL
Sharma	NULL
,	NULL
A.	NULL
Rao	NULL
,	NULL
and	NULL
P.	NULL
G.	NULL
Hogan	NULL
,	NULL
submitted	NULL
for	NULL
publication	NULL
.	NULL

20653	NULL
20654	NULL
target	NULL
of	NULL
CsA	NULL
.	NULL

A	NULL
related	NULL
cytoplasmic	NULL
protein	NULL
,	NULL
NFATc	NULL
,	NULL
has	NULL
been	NULL
characterized	NULL
in	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

Expression	NULL
of	NULL
NFAT	NULL
'	NULL
c	NULL
in	NULL
nonlymphoid	NULL
cells	NULL
is	NULL
able	NULL
to	NULL
activate	NULL
NFAT-driven	NULL
transcription	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
stimulation	NULL
as	NULL
well	NULL
as	NULL
confer	NULL
DNA-binding	NULL
activity	NULL
(	NULL
Northrop	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

The	NULL
DNA-binding	NULL
domains	NULL
of	NULL
both	NULL
NFATp	NULL
and	NULL
NFATe	NULL
display	NULL
a	NULL
distinct	NULL
sequence	NULL
similarity	NULL
with	NULL
the	NULL
Rel	NULL
homology	NULL
region	NULL
of	NULL
Rel	NULL
proteins	NULL
(	NULL
McCaffrey	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998b	NULL
;	NULL
Northrop	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

However	NULL
,	NULL
whereas	NULL
NFATp	NULL
is	NULL
constitutively	NULL
expressed	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
lymphoid	NULL
cells	NULL
and	NULL
in	NULL
certain	NULL
nonlymphoid	NULL
cells	NULL
(	NULL
Ho	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Wang	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
,	NULL
``	NULL
RNA	NULL
expression	NULL
of	NULL
NFATc	NULL
is	NULL
induced	NULL
by	NULL
PMA	NULL
and	NULL
ionomycin	NULL
stimulation	NULL
,	NULL
partially	NULL
inhibited	NULL
by	NULL
CsA	NULL
,	NULL
and	NULL
largely	NULL
restricted	NULL
to	NULL
T	NULL
cells	NULL
(	NULL
Northrop	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
it	NULL
has	NULL
recently	NULL
been	NULL
shown	NULL
that	NULL
NFAT	NULL
is	NULL
constitutively	NULL
nuclear	NULL
in	NULL
double-positive	NULL
thymocytes	NULL
(	NULL
Sen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
it	NULL
appears	NULL
that	NULL
T	NULL
cell-specific	NULL
,	NULL
CsA-sensitive	NULL
NFAT-mediated	NULL
transcription	NULL
is	NULL
a	NULL
complex	NULL
phenomenon	NULL
involving	NULL
more	NULL
than	NULL
one	NULL
protein	NULL
regulated	NULL
by	NULL
more	NULL
than	NULL
one	NULL
mechanism	NULL
.	NULL

We	NULL
have	NULL
recently	NULL
shown	NULL
that	NULL
NFAT	NULL
is	NULL
inducible	NULL
in	NULL
human	NULL
B	NULL
cells	NULL
upon	NULL
PMA/PHA	NULL
stimulation	NULL
and	NULL
that	NULL
a	NULL
constitutively	NULL
expressed	NULL
component	NULL
present	NULL
in	NULL
nuclear	NULL
extracts	NULL
of	NULL
unstimulated	NULL
transformed	NULL
B	NULL
and	NULL
T	NULL
cell	NULL
lines	NULL
is	NULL
necessary	NULL
and	NULL
sufficient	NULL
for	NULL
reconstituting	NULL
a	NULL
specific	NULL
NFAT	NULL
complex	NULL
in	NULL
association	NULL
with	NULL
recombinant	NULL
Fos	NULL
and	NULL
Jun	NULL
proteins	NULL
(	NULL
Yaseen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
,	NULL
1994	NULL
)	NULL
.	NULL

The	NULL
constitutive	NULL
component	NULL
is	NULL
therefore	NULL
similar	NULL
to	NULL
NFATp	NULL
in	NULL
its	NULL
ability	NULL
to	NULL
form	NULL
an	NULL
NFAT	NULL
complex	NULL
in	NULL
combination	NULL
with	NULL
Fos	NULL
and	NULL
Jun	NULL
proteins	NULL
.	NULL

However	NULL
,	NULL
its	NULL
presence	NULL
in	NULL
nuclear	NULL
extracts	NULL
of	NULL
unstimulated	NULL
human	NULL
B	NULL
and	NULL
T	NULL
cell	NULL
lines	NULL
raised	NULL
the	NULL
question	NULL
of	NULL
whether	NULL
and	NULL
how	NULL
CsA	NULL
inhibits	NULL
the	NULL
NFAT	NULL
activity	NULL
in	NULL
this	NULL
system	NULL
,	NULL
since	NULL
CsA	NULL
has	NULL
been	NULL
assumed	NULL
to	NULL
inhibit	NULL
NFAT	NULL
complex	NULL
formation	NULL
by	NULL
blocking	NULL
the	NULL
migration	NULL
of	NULL
a	NULL
cytoplasmic	NULL
component	NULL
to	NULL
the	NULL
nucleus	NULL
(	NULL
Flanagan	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
;	NULL
Schreiber	NULL
and	NULL
Crabtree	NULL
,	NULL
1992	NULL
)	NULL
.	NULL

In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
show	NULL
that	NULL
the	NULL
constitutive	NULL
factor	NULL
found	NULL
in	NULL
nuclear	NULL
extracts	NULL
of	NULL
unstimulated	NULL
B	NULL
and	NULL
T	NULL
cell	NULL
lines	NULL
is	NULL
a	NULL
human	NULL
homologue	NULL
of	NULL
murine	NULL
NFATp	NULL
and	NULL
that	NULL
its	NULL
ability	NULL
to	NULL
reconstitute	NULL
an	NULL
NFAT	NULL
complex	NULL
in	NULL
cooperation	NULL
with	NULL
Fos	NULL
and	NULL
Jun	NULL
is	NULL
inhibited	NULL
by	NULL
CsA	NULL
treatment	NULL
.	NULL

This	NULL
inhibition	NULL
is	NULL
due	NULL
to	NULL
loss	NULL
of	NULL
DNA-binding	NULL
activity	NULL
of	NULL
human	NULL
NFATp	NULL
resulting	NULL
from	NULL
an	NULL
increase	NULL
in	NULL
its	NULL
phosphorylation	NULL
level	NULL
as	NULL
in	NULL
vitro	NULL
phosphatase	NULL
treatment	NULL
completely	NULL
restores	NULL
DNA-binding	NULL
activity	NULL
of	NULL
the	NULL
factor	NULL
.	NULL

These	NULL
observations	NULL
demonstrate	NULL
an	NULL
additional	NULL
mechanism	NULL
for	NULL
CsA-mediated	NULL
inhibition	NULL
of	NULL
NFAT	NULL
complex	NULL
formation	NULL
.	NULL

EXPERIMENTAL	NULL
PROCEDURES	NULL
Cell	NULL
Culture	NULL
,	NULL
Stimulation	NULL
,	NULL
and	NULL
Cyclosporin	NULL
A	NULL
(	NULL
CsA	NULL
)	NULL
Treatment-Jurkat	NULL
and	NULL
Raji	NULL
cell	NULL
lines	NULL
purchased	NULL
from	NULL
ATCC	NULL
were	NULL
cultured	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
and	NULL
2	NULL
mM	NULL
glutamine	NULL
.	NULL

HeLa	NULL
cell	NULL
line	NULL
was	NULL
a	NULL
kind	NULL
gift	NULL
from	NULL
Dr.	NULL
Peter	NULL
Shank	NULL
and	NULL
was	NULL
cultured	NULL
in	NULL
Dulbecco	NULL
's	NULL
modified	NULL
Eagle	NULL
's	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
and	NULL
1	NULL
mM	NULL
sodium	NULL
pyrophosphate	NULL
.	NULL

Cell	NULL
lines	NULL
were	NULL
seeded	NULL
in	NULL
fresh	NULL
medium	NULL
at	NULL
2.5	NULL
X	NULL
10°	NULL
cells/ml	NULL
,	NULL
and	NULL
at	NULL
48	NULL
h	NULL
after	NULL
seeding	NULL
,	NULL
nuclear	NULL
and	NULL
cytoplasmic	NULL
extracts	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
below	NULL
.	NULL

Stimulation	NULL
of	NULL
cells	NULL
was	NULL
done	NULL
by	NULL
adding	NULL
2	NULL
ug/ml	NULL
PHA	NULL
and	NULL
50	NULL
ng/ml	NULL
PMA	NULL
to	NULL
cell	NULL
cultures	NULL
4	NULL
h	NULL
prior	NULL
to	NULL
nuclear	NULL
and	NULL
cytoplasmic	NULL
extrac-tions	NULL
.	NULL

For	NULL
CsA	NULL
studies	NULL
,	NULL
the	NULL
preliminary	NULL
experiments	NULL
suggested	NULL
that	NULL
CsA	NULL
(	NULL
Sandoz	NULL
)	NULL
could	NULL
be	NULL
used	NULL
at	NULL
1	NULL
ug/ml	NULL
concentration	NULL
for	NULL
1	NULL
h	NULL
to	NULL
24	NULL
h	NULL
without	NULL
affecting	NULL
cell	NULL
viability	NULL
or	NULL
data	NULL
reproducibility	NULL
.	NULL

Accordingly	NULL
,	NULL
cell	NULL
cultures	NULL
were	NULL
treated	NULL
with	NULL
1	NULL
ug/ml	NULL
of	NULL
CsA	NULL
(	NULL
Sandoz	NULL
)	NULL
for	NULL
16	NULL
h	NULL
prior	NULL
to	NULL
nuclear	NULL
and	NULL
cytoplasmic	NULL
extraction	NULL
.	NULL

Cell	NULL
Extraction-To	NULL
prepare	NULL
nuclear	NULL
and	NULL
cytoplasmic	NULL
extracts	NULL
,	NULL
1-2	NULL
x	NULL
10°	NULL
cells	NULL
were	NULL
harvested	NULL
by	NULL
centrifugation	NULL
,	NULL
washed	NULL
3	NULL
times	NULL
with	NULL
calci-um-deficient	NULL
phosphate-buffered	NULL
saline	NULL
,	NULL
and	NULL
resuspended	NULL
to	NULL
2.5	NULL
x	NULL
10	NULL
``	NULL
cells/ml	NULL
in	NULL
a	NULL
buffer	NULL
containing	NULL
10	NULL
mM	NULL
Tris	NULL
,	NULL
pH	NULL
7.4	NULL
,	NULL
10	NULL
mm	NULL
NaCl	NULL
,	NULL
3	NULL
mm	NULL
MgCl	NULL
,	NULL
,	NULL
0.5	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
2.5	NULL
mm	NULL
EGTA	NULL
,	NULL
protease	NULL
inhibitors	NULL
(	NULL
5	NULL
ug/ml	NULL
aprotinin	NULL
,	NULL
5	NULL
ug/ml	NULL
antipain	NULL
,	NULL
100	NULL
uM	NULL
benzamidine	NULL
,	NULL
5	NULL
ug/ml	NULL
leu-peptin	NULL
,	NULL
5	NULL
ug/ml	NULL
pepstatin	NULL
,	NULL
5	NULL
ug/ml	NULL
soybean	NULL
trypsin-chymotrypsin	NULL
inhib-itor	NULL
,	NULL
and	NULL
1	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
)	NULL
,	NULL
and	NULL
phosphatase	NULL
inhibitors	NULL
(	NULL
50	NULL
mM	NULL
NaF	NULL
and	NULL
20	NULL
mx	NULL
sodium	NULL
pyrophosphate	NULL
)	NULL
.	NULL

Resuspended	NULL
cells	NULL
were	NULL
lysed	NULL
by	NULL
adding	NULL
5	NULL
%	NULL
Nonidet	NULL
P-40	NULL
to	NULL
bring	NULL
the	NULL
final	NULL
concentration	NULL
of	NULL
Nonidet	NULL
P-40	NULL
to	NULL
0.05	NULL
%	NULL
and	NULL
incubated	NULL
on	NULL
ice	NULL
for	NULL
10	NULL
min	NULL
.	NULL

The	NULL
cell	NULL
Mechanism	NULL
for	NULL
Cyclosporin	NULL
A	NULL
Inhibition	NULL
of	NULL
NFAT	NULL
lysates	NULL
were	NULL
centrifuged	NULL
at	NULL
300	NULL
x	NULL
g	NULL
for	NULL
10	NULL
min	NULL
to	NULL
separate	NULL
nuclei	NULL
from	NULL
cytoplasmic	NULL
fraction	NULL
.	NULL

Nuclear	NULL
pellets	NULL
were	NULL
washed	NULL
once	NULL
with	NULL
1	NULL
ml	NULL
of	NULL
the	NULL
same	NULL
buffer	NULL
,	NULL
and	NULL
resuspended	NULL
in	NULL
300-400	NULL
pl	NULL
of	NULL
a	NULL
nuclear	NULL
extraction	NULL
buffer	NULL
containing	NULL
20	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.9	NULL
,	NULL
0.42	NULL
M	NULL
NaCl	NULL
,	NULL
1.5	NULL
mm	NULL
MgCl	NULL
,	NULL
,	NULL
25	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
glycerol	NULL
,	NULL
0.2	NULL
mM	NULL
EDTA	NULL
,	NULL
0.5	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
and	NULL
the	NULL
above	NULL
protease	NULL
inhibitors	NULL
.	NULL

Resuspended	NULL
nuclei	NULL
were	NULL
incubated	NULL
on	NULL
ice	NULL
for	NULL
30	NULL
min	NULL
with	NULL
occasional	NULL
shaking	NULL
to	NULL
extract	NULL
the	NULL
nuclear	NULL
proteins	NULL
and	NULL
finally	NULL
spun	NULL
down	NULL
in	NULL
a	NULL
microcentrifuge	NULL
for	NULL
5	NULL
min	NULL
.	NULL

The	NULL
supernatant	NULL
with	NULL
nuclear	NULL
proteins	NULL
was	NULL
dialyzed	NULL
against	NULL
a	NULL
dialysis	NULL
buffer	NULL
(	NULL
20	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.9	NULL
,	NULL
100	NULL
mm	NULL
KCl	NULL
,	NULL
0.2	NULL
mM	NULL
EDTA	NULL
,	NULL
20	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
glycerol	NULL
,	NULL
1	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
,	NULL
and	NULL
0.5	NULL
mM	NULL
dithiothreitol	NULL
)	NULL
.	NULL

For	NULL
preparation	NULL
of	NULL
cytoplasmic	NULL
fractions	NULL
,	NULL
the	NULL
300	NULL
x	NULL
g	NULL
supernatant	NULL
was	NULL
further	NULL
centrifuged	NULL
at	NULL
100,000	NULL
x	NULL
g	NULL
for	NULL
1	NULL
h.	NULL
Cytoplasmic	NULL
proteins	NULL
in	NULL
the	NULL
supernatant	NULL
were	NULL
precipitated	NULL
at	NULL
1.5	NULL
M	NULL
ammonium	NULL
sulfate	NULL
for	NULL
30	NULL
min	NULL
on	NULL
ice	NULL
,	NULL
and	NULL
the	NULL
precipitated	NULL
proteins	NULL
were	NULL
collected	NULL
by	NULL
centrifuga-tion	NULL
at	NULL
100,000	NULL
x	NULL
g	NULL
for	NULL
30	NULL
min	NULL
.	NULL

The	NULL
protein	NULL
pellets	NULL
were	NULL
resuspended	NULL
in	NULL
the	NULL
dialysis	NULL
buffer	NULL
supplemented	NULL
with	NULL
the	NULL
above	NULL
protease	NULL
inhibitors	NULL
,	NULL
and	NULL
dialyzed	NULL
extensively	NULL
against	NULL
the	NULL
dialysis	NULL
buffer	NULL
.	NULL

The	NULL
protein	NULL
concentration	NULL
was	NULL
determined	NULL
using	NULL
the	NULL
Bio-Rad	NULL
protein	NULL
assay	NULL
kit	NULL
with	NULL
bovine	NULL
serum	NULL
albumin	NULL
as	NULL
a	NULL
standard	NULL
.	NULL

Oligonucleotides	NULL
Used	NULL
in	NULL
DNA	NULL
Binding-Human	NULL
NFAT	NULL
oligonucleotide	NULL
is	NULL
a	NULL
30-mer	NULL
containing	NULL
the	NULL
NFAT	NULL
binding	NULL
site	NULL
from	NULL
the	NULL
IL-2	NULL
pro-moter	NULL
,	NULL
and	NULL
its	NULL
sequence	NULL
is	NULL
5-GGAGGAAAAACTGTTTCATACAGAAG-GCGT-3	NULL
'	NULL
(	NULL
Emmel	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

The	NULL
murine	NULL
NFAT	NULL
oligonucleotide	NULL
from	NULL
the	NULL
distal	NULL
NFAT	NULL
site	NULL
of	NULL
the	NULL
murine	NULL
IL-2	NULL
promoter	NULL
is	NULL
a	NULL
33-mer	NULL
,	NULL
and	NULL
its	NULL
sequence	NULL
|	NULL
is	NULL
-	NULL
5'-gateGCCCAAAGAGGAAAATTTGTTTCATACAG-3	NULL
'	NULL
(	NULL
Jain	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993b	NULL
)	NULL
.	NULL

The	NULL
oligonucleotide	NULL
used	NULL
as	NULL
a	NULL
nonspecific	NULL
competitor	NULL
contains	NULL
a	NULL
5'-purine-rich	NULL
motif	NULL
,	NULL
and	NULL
its	NULL
sequence	NULL
is	NULL
5'-AAGAAG-GAGAAAATACCTTTTTGATTTTCACA-3	NULL
'	NULL
.	NULL

Double-stranded	NULL
oligonucleotides	NULL
were	NULL
prepared	NULL
by	NULL
reannealing	NULL
of	NULL
synthetic	NULL
single-stranded	NULL
oligonucleotides	NULL
purchased	NULL
from	NULL
Research	NULL
Genetics	NULL
and	NULL
labeled	NULL
with	NULL
[	NULL
a-*°P	NULL
]	NULL
dCTP	NULL
(	NULL
3000	NULL
Ci/mmol	NULL
,	NULL
Amersham	NULL
Corp.	NULL
)	NULL
by	NULL
filling	NULL
in	NULL
the	NULL
recessed	NULL
ends	NULL
using	NULL
Klenow	NULL
enzyme	NULL
.	NULL

Electrophoretic	NULL
Mobility	NULL
Shift	NULL
Assay-Binding	NULL
reactions	NULL
have	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
Yaseen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
5	NULL
or	NULL
10	NULL
ug	NULL
of	NULL
nuclear	NULL
proteins	NULL
were	NULL
incubated	NULL
at	NULL
room	NULL
temperature	NULL
in	NULL
a	NULL
DNA	NULL
binding	NULL
buffer	NULL
containing	NULL
10	NULL
mm	NULL
Tris	NULL
,	NULL
pH	NULL
7.5	NULL
,	NULL
50	NULL
mM	NULL
NaCl	NULL
,	NULL
1	NULL
mm	NULL
EDTA	NULL
,	NULL
1	NULL
mm	NULL
2-mercaptoethanol	NULL
,	NULL
1	NULL
%	NULL
Ficoll	NULL
(	NULL
M	NULL
,	NULL
400,000	NULL
)	NULL
,	NULL
and	NULL
300	NULL
ng	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
along	NULL
with	NULL
cold	NULL
competitors	NULL
,	NULL
if	NULL
any	NULL
.	NULL

After	NULL
a	NULL
10-min	NULL
incubation	NULL
,	NULL
0.1-0.25	NULL
ng	NULL
of	NULL
radioactive	NULL
NFAT	NULL
oligonucleotide	NULL
probe	NULL
was	NULL
added	NULL
,	NULL
and	NULL
the	NULL
incubation	NULL
was	NULL
continued	NULL
for	NULL
20	NULL
min	NULL
.	NULL

For	NULL
supershift	NULL
assays	NULL
,	NULL
1	NULL
pl	NULL
of	NULL
1/10-diluted	NULL
rabbit	NULL
antisera	NULL
specific	NULL
to	NULL
murine	NULL
NFATp	NULL
was	NULL
added	NULL
to	NULL
binding	NULL
reactions	NULL
,	NULL
and	NULL
the	NULL
incubation	NULL
was	NULL
continued	NULL
for	NULL
a	NULL
further	NULL
10	NULL
min	NULL
.	NULL

Two	NULL
rabbit	NULL
antisera	NULL
raised	NULL
against	NULL
either	NULL
recombinant	NULL
NFATp	NULL
(	NULL
R59	NULL
)	NULL
or	NULL
an	NULL
amino-terminal	NULL
peptide	NULL
fragment	NULL
(	NULL
67.1	NULL
)	NULL
of	NULL
NFATp	NULL
were	NULL
used	NULL
(	NULL
McCaffrey	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993b	NULL
;	NULL
Ho	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

For	NULL
NFAT	NULL
reconstitution	NULL
with	NULL
recombinant	NULL
Fos	NULL
and	NULL
Jun	NULL
proteins	NULL
,	NULL
and	NULL
DNA	NULL
binding	NULL
to	NULL
the	NULL
murine	NULL
oligonucleotide	NULL
,	NULL
the	NULL
binding	NULL
buffer	NULL
used	NULL
was	NULL
identical	NULL
to	NULL
the	NULL
above	NULL
except	NULL
that	NULL
5	NULL
mM	NULL
dithiothreitol	NULL
was	NULL
substituted	NULL
for	NULL
2-mercapto-ethanol	NULL
and	NULL
0.2	NULL
mg/ml	NULL
bovine	NULL
serum	NULL
albumin	NULL
was	NULL
added	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
Yaseen	NULL
ef	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

Purified	NULL
recombinant	NULL
Fos	NULL
and	NULL
Jun	NULL
proteins	NULL
(	NULL
Kerppola	NULL
and	NULL
Curran	NULL
,	NULL
1991	NULL
)	NULL
were	NULL
a	NULL
kind	NULL
gift	NULL
from	NULL
Dr.	NULL
Tom	NULL
Kerppola	NULL
and	NULL
Dr.	NULL
Tom	NULL
Curran	NULL
.	NULL

In	NULL
Vitro	NULL
Phosphatase	NULL
Treatment-Nuclear	NULL
extract	NULL
(	NULL
40	NULL
ug	NULL
)	NULL
from	NULL
either	NULL
CsA-untreated	NULL
or	NULL
treated	NULL
cells	NULL
was	NULL
mixed	NULL
with	NULL
3	NULL
units	NULL
of	NULL
calf	NULL
intestinal	NULL
alkaline	NULL
phosphatase	NULL
(	NULL
AP	NULL
)	NULL
(	NULL
Pharmacia	NULL
Biotech	NULL
Inc.	NULL
)	NULL
in	NULL
a	NULL
buffer	NULL
containing	NULL
20	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.4	NULL
,	NULL
50	NULL
mm	NULL
KCl	NULL
,	NULL
2.5	NULL
mm	NULL
MgC	NULL
]	NULL
;	NULL
,	NULL
0.1	NULL
mm	NULL
EDTA	NULL
,	NULL
10	NULL
%	NULL
glycerol	NULL
,	NULL
0.5	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
incubated	NULL
at	NULL
30	NULL
°C	NULL
for	NULL
15	NULL
min	NULL
.	NULL

For	NULL
CaN	NULL
treatment	NULL
,	NULL
the	NULL
same	NULL
amount	NULL
of	NULL
nuclear	NULL
extract	NULL
was	NULL
mixed	NULL
with	NULL
2	NULL
ug	NULL
of	NULL
CaN	NULL
(	NULL
Upstate	NULL
Biotechnology	NULL
Inc.	NULL
)	NULL
and	NULL
1	NULL
ug	NULL
of	NULL
calmodulin	NULL
(	NULL
Upstate	NULL
Biotechnology	NULL
Inc.	NULL
)	NULL
in	NULL
the	NULL
same	NULL
buffer	NULL
except	NULL
that	NULL
1.5	NULL
mM	NULL
MnCl	NULL
,	NULL
was	NULL
added	NULL
and	NULL
incubated	NULL
at	NULL
30	NULL
°C	NULL
for	NULL
15	NULL
min	NULL
.	NULL

According	NULL
to	NULL
manufacturers	NULL
,	NULL
CaN	NULL
has	NULL
a	NULL
specific	NULL
activity	NULL
of	NULL
1	NULL
unit/mg	NULL
,	NULL
and	NULL
AP	NULL
has	NULL
a	NULL
specific	NULL
activity	NULL
of	NULL
2300	NULL
units/mg	NULL
,	NULL
as	NULL
measured	NULL
by	NULL
hydrolysis	NULL
of	NULL
p-nitrophenyl	NULL
phos-phate	NULL
.	NULL

For	NULL
the	NULL
dose-dependent	NULL
effect	NULL
of	NULL
CaN	NULL
and	NULL
AP	NULL
on	NULL
dephosphorylation	NULL
of	NULL
NFATp	NULL
(	NULL
Fig	NULL
.	NULL

4C	NULL
)	NULL
,	NULL
increasing	NULL
amounts	NULL
of	NULL
CaN	NULL
and	NULL
AP	NULL
were	NULL
used	NULL
as	NULL
indicated	NULL
in	NULL
the	NULL
figure	NULL
legend	NULL
.	NULL

For	NULL
inhibition	NULL
of	NULL
the	NULL
phosphatase	NULL
activity	NULL
of	NULL
AP	NULL
and	NULL
CaN	NULL
,	NULL
20	NULL
mM	NULL
sodium	NULL
pyrophosphate	NULL
and	NULL
50	NULL
mM	NULL
NaF	NULL
were	NULL
added	NULL
to	NULL
reaction	NULL
mixtures	NULL
before	NULL
the	NULL
incubation	NULL
.	NULL

Heat	NULL
inactivation	NULL
of	NULL
CaN	NULL
was	NULL
conducted	NULL
for	NULL
10	NULL
min	NULL
at	NULL
75	NULL
°C	NULL
before	NULL
adding	NULL
to	NULL
nuclear	NULL
extract	NULL
.	NULL

Control	NULL
nuclear	NULL
extracts	NULL
were	NULL
mixed	NULL
with	NULL
the	NULL
same	NULL
volume	NULL
of	NULL
buffer	NULL
but	NULL
without	NULL
phosphatase	NULL
and	NULL
incubated	NULL
at	NULL
30	NULL
°C	NULL
for	NULL
15	NULL
min	NULL
.	NULL

Immunoblot	NULL
Analysis-Nuclear	NULL
and	NULL
cytoplasmic	NULL
proteins	NULL
were	NULL
separated	NULL
on	NULL
a	NULL
7	NULL
%	NULL
SDS-polyacrylamide	NULL
gel	NULL
and	NULL
transferred	NULL
to	NULL
a	NULL
nitrocellulose	NULL
membrane	NULL
.	NULL

The	NULL
filter	NULL
was	NULL
incubated	NULL
in	NULL
TBS-T	NULL
(	NULL
10	NULL
mm	NULL
Tris	NULL
,	NULL
pH	NULL
7.6	NULL
,	NULL
150	NULL
mm	NULL
NaCl	NULL
,	NULL
0.2	NULL
%	NULL
Tween	NULL
20	NULL
)	NULL
containing	NULL
5	NULL
%	NULL
nonfat	NULL
dry	NULL
milk	NULL
overnight	NULL
at	NULL
4	NULL
°C	NULL
.	NULL

First	NULL
antibody	NULL
incubation	NULL
was	NULL
carried	NULL
out	NULL
in	NULL
TBS-T	NULL
Mechanism	NULL
for	NULL
Cyclosporin	NULL
A	NULL
Inhibition	NULL
of	NULL
NFAT	NULL
containing	NULL
2	NULL
%	NULL
bovine	NULL
serum	NULL
albumin	NULL
using	NULL
1:3000-diluted	NULL
R59	NULL
anti-serum	NULL
.	NULL

Following	NULL
incubation	NULL
for	NULL
3	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
,	NULL
the	NULL
membrane	NULL
was	NULL
rinsed	NULL
in	NULL
TBS-T	NULL
,	NULL
incubated	NULL
with	NULL
secondary	NULL
antibody	NULL
,	NULL
a	NULL
donkey	NULL
anti-rabbit	NULL
IgG	NULL
antibody	NULL
conjugated	NULL
to	NULL
horseradish	NULL
peroxidase	NULL
(	NULL
Amersham	NULL
Corp.	NULL
)	NULL
,	NULL
for	NULL
1	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
,	NULL
and	NULL
then	NULL
rinsed	NULL
again	NULL
.	NULL

The	NULL
membrane	NULL
was	NULL
developed	NULL
using	NULL
the	NULL
enhanced	NULL
chemiluminesence	NULL
(	NULL
ECL	NULL
)	NULL
detection	NULL
system	NULL
(	NULL
Amersham	NULL
Corp.	NULL
)	NULL
.	NULL

For	NULL
immunoblotting	NULL
of	NULL
H	NULL
subunit	NULL
of	NULL
lactate	NULL
dehydrogenase	NULL
(	NULL
LDH	NULL
)	NULL
and	NULL
transcription	NULL
factor	NULL
USF	NULL
,	NULL
equal	NULL
amounts	NULL
of	NULL
nuclear	NULL
and	NULL
cytoplasmic	NULL
extracts	NULL
were	NULL
fractionated	NULL
on	NULL
a	NULL
10	NULL
%	NULL
SDS-polyacrylamide	NULL
gel	NULL
,	NULL
and	NULL
transferred	NULL
to	NULL
a	NULL
nitrocellulose	NULL
membrane	NULL
.	NULL

The	NULL
rest	NULL
of	NULL
the	NULL
procedure	NULL
was	NULL
the	NULL
same	NULL
as	NULL
that	NULL
used	NULL
for	NULL
NFATp	NULL
immunoblotting	NULL
except	NULL
for	NULL
the	NULL
first	NULL
and	NULL
second	NULL
antibodies	NULL
used	NULL
.	NULL

A	NULL
monoclonal	NULL
mouse	NULL
anti-human	NULL
LDH	NULL
antibody	NULL
(	NULL
Sigma	NULL
)	NULL
and	NULL
1:2000-diluted	NULL
goat	NULL
anti-mouse	NULL
IgG	NULL
antibodies	NULL
conjugated	NULL
to	NULL
horseradish	NULL
peroxidase	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotech	NULL
.	NULL
)	NULL

were	NULL
used	NULL
for	NULL
first	NULL
and	NULL
second	NULL
antibody	NULL
incubations	NULL
,	NULL
respectively	NULL
.	NULL

After	NULL
detecting	NULL
LDH	NULL
by	NULL
ECL	NULL
system	NULL
,	NULL
horseradish	NULL
peroxidase	NULL
on	NULL
the	NULL
filter	NULL
was	NULL
inactivated	NULL
by	NULL
incubation	NULL
in	NULL
Tris-buffered	NULL
saline	NULL
containing	NULL
0.2	NULL
%	NULL
Tween	NULL
20	NULL
and	NULL
15	NULL
%	NULL
hydrogen	NULL
peroxide	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
30	NULL
min	NULL
.	NULL

The	NULL
filter	NULL
was	NULL
reprobed	NULL
with	NULL
0.2	NULL
ug/ml	NULL
of	NULL
rabbit	NULL
anti-USF	NULL
antibodies	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotech	NULL
.	NULL
)	NULL

,	NULL
and	NULL
a	NULL
donkey	NULL
anti-rabbit	NULL
IgG	NULL
antibody	NULL
conjugated	NULL
to	NULL
horseradish	NULL
peroxidase	NULL
was	NULL
used	NULL
as	NULL
a	NULL
secondary	NULL
antibody	NULL
.	NULL

*P	NULL
Labeling	NULL
and	NULL
Immunoprecipitation-Raji	NULL
cells	NULL
(	NULL
2	NULL
X	NULL
10°	NULL
cells	NULL
)	NULL
were	NULL
washed	NULL
3	NULL
times	NULL
with	NULL
phosphate-free	NULL
RPMI	NULL
1640	NULL
,	NULL
equally	NULL
divided	NULL
into	NULL
two	NULL
flasks	NULL
,	NULL
and	NULL
incubated	NULL
with	NULL
0.5	NULL
mCi	NULL
of	NULL
in	NULL
10	NULL
ml	NULL
of	NULL
phosphate-free	NULL
medium	NULL
for	NULL
1	NULL
h.	NULL
One	NULL
of	NULL
the	NULL
flasks	NULL
was	NULL
treated	NULL
with	NULL
1	NULL
ug/ml	NULL
CsA	NULL
,	NULL
while	NULL
an	NULL
appropriate	NULL
concentration	NULL
of	NULL
ethanol	NULL
was	NULL
added	NULL
to	NULL
untreated	NULL
culture	NULL
as	NULL
vehicle	NULL
control	NULL
.	NULL

After	NULL
incubation	NULL
for	NULL
another	NULL
2	NULL
h	NULL
,	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
and	NULL
quantitated	NULL
as	NULL
described	NULL
previously	NULL
.	NULL

Nuclear	NULL
protein	NULL
(	NULL
300	NULL
ug	NULL
)	NULL
from	NULL
CsA-treated	NULL
cells	NULL
was	NULL
incubated	NULL
with	NULL
4	NULL
ug	NULL
of	NULL
CaN	NULL
as	NULL
described	NULL
previously	NULL
,	NULL
and	NULL
then	NULL
CaN-treated	NULL
and	NULL
untreated	NULL
nuclear	NULL
proteins	NULL
were	NULL
precleared	NULL
with	NULL
protein	NULL
A-Sepharose	NULL
in	NULL
TEN	NULL
buffer	NULL
(	NULL
50	NULL
mm	NULL
Tris	NULL
,	NULL
pH	NULL
7.6	NULL
,	NULL
150	NULL
mM	NULL
NaCl	NULL
,	NULL
and	NULL
1	NULL
mM	NULL
EDTA	NULL
)	NULL
including	NULL
1	NULL
mg/ml	NULL
bovine	NULL
serum	NULL
albumin	NULL
,	NULL
protease	NULL
inhibitors	NULL
(	NULL
same	NULL
as	NULL
used	NULL
for	NULL
nuclear	NULL
extraction	NULL
)	NULL
,	NULL
and	NULL
phosphatase	NULL
inhibitors	NULL
(	NULL
10	NULL
mM	NULL
sodium	NULL
pyrophosphate	NULL
and	NULL
25	NULL
mM	NULL
NaF	NULL
)	NULL
.	NULL

NFATp	NULL
was	NULL
immunoprecipitated	NULL
for	NULL
3	NULL
h	NULL
with	NULL
R59	NULL
antiserum	NULL
and	NULL
protein	NULL
A-Sepharose	NULL
,	NULL
and	NULL
immunoprecipitates	NULL
were	NULL
washed	NULL
3	NULL
times	NULL
with	NULL
the	NULL
above	NULL
buffer	NULL
containing	NULL
0.3	NULL
M	NULL
KCl	NULL
instead	NULL
of	NULL
NaCl	NULL
.	NULL

Immunoprecipitated	NULL
proteins	NULL
were	NULL
separated	NULL
on	NULL
a	NULL
SDS-polyacrylamide	NULL
gel	NULL
,	NULL
transferred	NULL
to	NULL
nitrocellulose	NULL
,	NULL
and	NULL
then	NULL
subjected	NULL
to	NULL
immunoblot	NULL
analysis	NULL
using	NULL
R59	NULL
antiserum	NULL
to	NULL
compare	NULL
recovery	NULL
of	NULL
NFAT	NULL
p	NULL
from	NULL
different	NULL
samples	NULL
.	NULL

After	NULL
luminescence	NULL
on	NULL
the	NULL
membrane	NULL
disappeared	NULL
,	NULL
the	NULL
same	NULL
membrane	NULL
was	NULL
scanned	NULL
by	NULL
a	NULL
PhosphorImager	NULL
to	NULL
detect	NULL
*°P-labeled	NULL
NFATp	NULL
.	NULL

RESULTS	NULL
The	NULL
Constitutive	NULL
Component	NULL
of	NULL
NFAT	NULL
Is	NULL
a	NULL
Target	NULL
of	NULL
CsA-We	NULL
have	NULL
previously	NULL
shown	NULL
that	NULL
NFAT	NULL
binding	NULL
activity	NULL
is	NULL
inducible	NULL
in	NULL
human	NULL
B	NULL
cells	NULL
(	NULL
Yaseen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
,	NULL
and	NULL
this	NULL
observation	NULL
has	NULL
been	NULL
recently	NULL
confirmed	NULL
in	NULL
activated	NULL
murine	NULL
B	NULL
cells	NULL
(	NULL
Choi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Venkataraman	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

To	NULL
test	NULL
whether	NULL
NFAT	NULL
induction	NULL
in	NULL
human	NULL
B	NULL
cells	NULL
is	NULL
sensitive	NULL
to	NULL
CsA	NULL
as	NULL
is	NULL
the	NULL
case	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
Emmel	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Mattilla	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Jain	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
,	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
Raji	NULL
B	NULL
cells	NULL
(	NULL
a	NULL
human	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
cell	NULL
line	NULL
)	NULL
and	NULL
Jurkat	NULL
T	NULL
cells	NULL
(	NULL
a	NULL
human	NULL
T	NULL
cell	NULL
lymphoma	NULL
cell	NULL
line	NULL
)	NULL
stimulated	NULL
with	NULL
PMA	NULL
and	NULL
PHA	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
CsA	NULL
.	NULL

These	NULL
extracts	NULL
were	NULL
then	NULL
analyzed	NULL
for	NULL
binding	NULL
activity	NULL
to	NULL
a	NULL
human	NULL
IL-2	NULL
NFAT	NULL
oligonucleotide	NULL
in	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
(	NULL
EMSA	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
B	NULL
and	NULL
T	NULL
cells	NULL
stimulated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
CsA	NULL
were	NULL
lacking	NULL
in	NULL
NFAT	NULL
binding	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
4	NULL
compared	NULL
with	NULL
lanes	NULL
1	NULL
and	NULL
3	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
CsA	NULL
prevented	NULL
the	NULL
induction	NULL
of	NULL
NFAT	NULL
binding	NULL
in	NULL
B	NULL
as	NULL
well	NULL
as	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
demonstrated	NULL
that	NULL
a	NULL
constitutive	NULL
component	NULL
present	NULL
in	NULL
nuclear	NULL
extracts	NULL
of	NULL
unstimulated	NULL
human	NULL
B	NULL
and	NULL
T	NULL
cell	NULL
lines	NULL
could	NULL
reconstitute	NULL
an	NULL
NFAT	NULL
complex	NULL
in	NULL
association	NULL
with	NULL
purified	NULL
recombinant	NULL
Fos	NULL
and	NULL
Jun	NULL
proteins	NULL
(	NULL
Yaseen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
,	NULL
1994	NULL
)	NULL
.	NULL

Since	NULL
Fos	NULL
and	NULL
Jun	NULL
induction	NULL
is	NULL
not	NULL
sensitive	NULL
to	NULL
CsA	NULL
,	NULL
it	NULL
was	NULL
likely	NULL
that	NULL
the	NULL
target	NULL
for	NULL
CsA	NULL
inhibition	NULL
in	NULL
NFAT	NULL
was	NULL
the	NULL
constitutive	NULL
component	NULL
found	NULL
in	NULL
unstimulated	NULL
B	NULL
and	NULL
T	NULL
cells	NULL
.	NULL

To	NULL
find	NULL
out	NULL
whether	NULL
the	NULL
constitutive	NULL
component	NULL
is	NULL
a	NULL
target	NULL
of	NULL
CsA	NULL
,	NULL
nuclear	NULL
extracts	NULL
from	NULL
unstimulated	NULL
Raji	NULL
B	NULL
and	NULL
Jurkat	NULL
T	NULL
cells	NULL
treated	NULL
with	NULL
or	NULL
without	NULL
CsA	NULL
were	NULL
tested	NULL
for	NULL
their	NULL
20655	NULL
A	NULL
B	NULL
Raji	NULL
Jurkat	NULL
Jurkat	NULL
Raji	NULL
f	NULL
?	NULL

sk	NULL
-CsA	NULL
+CsA	NULL
-	NULL
-Cs	NULL
+Cs	NULL
.	NULL

CsA	NULL
-	NULL
+o	NULL
-	NULL
+	NULL
&	NULL
f~-s	NULL
f	NULL
--	NULL
-	NULL
Fos/Jun	NULL
~o	NULL
$	NULL
%	NULL
%	NULL
o	NULL
go	NULL
®	NULL
%	NULL
&	NULL
NFAT	NULL
-	NULL
»	NULL
~	NULL
.	NULL

NFAT	NULL
-*	NULL
.	NULL

.	NULL

«	NULL
>	NULL
*	NULL
-	NULL
@	NULL
0ODDOC®	NULL
Free	NULL
Probe	NULL
10	NULL
r	NULL
:	NULL
3	NULL
4	NULL
102	NULL
3	NULL
4	NULL
5	NULL
60	NULL
7	NULL
8	NULL
Fic	NULL
.	NULL

1	NULL
.	NULL

CsA	NULL
inhibits	NULL
DNA	NULL
binding	NULL
activity	NULL
of	NULL
the	NULL
constitutive	NULL
component	NULL
of	NULL
NFAT	NULL
in	NULL
human	NULL
lymphocytes	NULL
.	NULL

A	NULL
,	NULL
inhibition	NULL
of	NULL
inducible	NULL
NFAT	NULL
complex	NULL
in	NULL
T	NULL
and	NULL
B	NULL
cells	NULL
by	NULL
CsA	NULL
treatment	NULL
.	NULL

EMSA	NULL
using	NULL
a	NULL
radioactive	NULL
probe	NULL
containing	NULL
the	NULL
human	NULL
IL-2	NULL
NFAT	NULL
site	NULL
was	NULL
performed	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
Jurkat	NULL
(	NULL
a	NULL
T	NULL
cell	NULL
line	NULL
)	NULL
and	NULL
Raji	NULL
(	NULL
a	NULL
B	NULL
cell	NULL
line	NULL
)	NULL
stimulated	NULL
with	NULL
50	NULL
ng/ml	NULL
PMA	NULL
and	NULL
2	NULL
ug/ml	NULL
PHA	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
3	NULL
)	NULL
or	NULL
presence	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
4	NULL
)	NULL
of	NULL
1	NULL
ug/ml	NULL
CsA	NULL
.	NULL

NFAT	NULL
induction	NULL
was	NULL
inhibited	NULL
in	NULL
both	NULL
B	NULL
and	NULL
T	NULL
cells	NULL
by	NULL
CsA	NULL
treatment	NULL
.	NULL

Arrows	NULL
indicate	NULL
NFAT	NULL
complexes	NULL
and	NULL
free	NULL
probe	NULL
.	NULL

B	NULL
,	NULL
EMSA	NULL
was	NULL
performed	NULL
using	NULL
nuclear	NULL
extracts	NULL
from	NULL
unstimulated	NULL
Raji	NULL
B	NULL
and	NULL
Jurkat	NULL
T	NULL
cells	NULL
,	NULL
either	NULL
untreated	NULL
(	NULL
lanes	NULL
1	NULL
,	NULL
2	NULL
,	NULL
5	NULL
,	NULL
and	NULL
6	NULL
)	NULL
or	NULL
treated	NULL
(	NULL
lanes	NULL
3	NULL
,	NULL
4	NULL
,	NULL
7	NULL
,	NULL
and	NULL
8	NULL
)	NULL
with	NULL
1	NULL
ug/ml	NULL
of	NULL
CsA	NULL
.	NULL

Extracts	NULL
were	NULL
incubated	NULL
with	NULL
a	NULL
labeled	NULL
human	NULL
IL-2	NULL
NFAT	NULL
oligonucleotide	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
odd-numbered	NULL
lanes	NULL
)	NULL
or	NULL
presence	NULL
(	NULL
even-numbered	NULL
lanes	NULL
)	NULL
of	NULL
125	NULL
nM	NULL
recombinant	NULL
Fos/Jun	NULL
heterodimers	NULL
.	NULL

ability	NULL
to	NULL
cooperate	NULL
with	NULL
recombinant	NULL
Fos/Jun	NULL
heterodimers	NULL
in	NULL
NFAT	NULL
reconstitution	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
nuclear	NULL
extracts	NULL
of	NULL
CsA-untreated	NULL
B	NULL
and	NULL
T	NULL
cells	NULL
were	NULL
able	NULL
to	NULL
reconstitute	NULL
an	NULL
NFAT	NULL
complex	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
6	NULL
)	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
those	NULL
of	NULL
CsA-treated	NULL
cells	NULL
lost	NULL
most	NULL
of	NULL
their	NULL
ability	NULL
to	NULL
reconstitute	NULL
an	NULL
NFAT	NULL
complex	NULL
(	NULL
lanes	NULL
4	NULL
and	NULL
8	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
the	NULL
constitutive	NULL
component	NULL
of	NULL
NFAT	NULL
is	NULL
a	NULL
target	NULL
of	NULL
CsA	NULL
,	NULL
but	NULL
they	NULL
do	NULL
not	NULL
show	NULL
whether	NULL
CsA	NULL
treatment	NULL
leads	NULL
to	NULL
loss	NULL
of	NULL
the	NULL
component	NULL
from	NULL
lymphocyte	NULL
nuclei	NULL
or	NULL
to	NULL
its	NULL
modification	NULL
in	NULL
a	NULL
way	NULL
that	NULL
prevents	NULL
it	NULL
from	NULL
binding	NULL
to	NULL
DNA	NULL
.	NULL

The	NULL
Constitutive	NULL
Component	NULL
of	NULL
NFAT	NULL
Is	NULL
a	NULL
Homologue	NULL
of	NULL
the	NULL
Murine	NULL
Pre-existing	NULL
Component	NULL
of	NULL
NFAT	NULL
(	NULL
NFAT	NULL
observation	NULL
that	NULL
the	NULL
constitutive	NULL
component	NULL
is	NULL
not	NULL
only	NULL
a	NULL
pre-existing	NULL
subunit	NULL
of	NULL
NFAT	NULL
but	NULL
a	NULL
potential	NULL
target	NULL
of	NULL
CsA-mediated	NULL
inhibition	NULL
of	NULL
NFAT	NULL
induction	NULL
suggested	NULL
that	NULL
this	NULL
factor	NULL
might	NULL
be	NULL
related	NULL
to	NULL
NFATp	NULL
.	NULL

To	NULL
test	NULL
this	NULL
possibility	NULL
,	NULL
we	NULL
utilized	NULL
antisera	NULL
against	NULL
murine	NULL
NFATp	NULL
(	NULL
McCaffrey	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993b	NULL
;	NULL
Ho	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
in	NULL
``	NULL
supershift	NULL
``	NULL
assays	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Incubation	NULL
of	NULL
nuclear	NULL
extracts	NULL
with	NULL
the	NULL
preimmune	NULL
serum	NULL
had	NULL
no	NULL
effect	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
6	NULL
)	NULL
,	NULL
while	NULL
two	NULL
antisera	NULL
against	NULL
murine	NULL
NFATp	NULL
supershifted	NULL
native	NULL
NFAT	NULL
complexes	NULL
from	NULL
stimulated	NULL
Raji	NULL
cells	NULL
(	NULL
Zanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
as	NULL
well	NULL
as	NULL
NFAT	NULL
complexes	NULL
reconstituted	NULL
by	NULL
combining	NULL
nuclear	NULL
extracts	NULL
from	NULL
unstimulated	NULL
cells	NULL
with	NULL
Fos/Jun	NULL
heterodimers	NULL
(	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
Jurkat	NULL
cells	NULL
,	NULL
and	NULL
several	NULL
other	NULL
NFATp-specific	NULL
antisera	NULL
such	NULL
as	NULL
a	NULL
«	NULL
-72	NULL
,	NULL
«	NULL
-25.1	NULL
,	NULL
and	NULL
«	NULL
-R89	NULL
also	NULL
recognized	NULL
human	NULL
NFAT	NULL
complexes	NULL
in	NULL
EMSA	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Differences	NULL
in	NULL
the	NULL
migration	NULL
of	NULL
supershifted	NULL
complexes	NULL
by	NULL
the	NULL
two	NULL
antisera	NULL
is	NULL
likely	NULL
due	NULL
to	NULL
the	NULL
nature	NULL
of	NULL
the	NULL
antisera	NULL
,	NULL
namely	NULL
anti-recombinant	NULL
NFATp	NULL
(	NULL
Ab1	NULL
)	NULL
and	NULL
anti-peptide	NULL
(	NULL
67.1	NULL
)	NULL
(	NULL
A52	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
with	NULL
immunoblot	NULL
analyses	NULL
using	NULL
antiserum	NULL
against	NULL
NFATp	NULL
(	NULL
Figs	NULL
.	NULL

3	NULL
and	NULL
4	NULL
)	NULL
,	NULL
these	NULL
data	NULL
strongly	NULL
suggest	NULL
that	NULL
the	NULL
constitutive	NULL
component	NULL
detected	NULL
in	NULL
nuclear	NULL
extracts	NULL
of	NULL
B	NULL
and	NULL
T	NULL
cell	NULL
lines	NULL
is	NULL
a	NULL
20656	NULL
Raji	NULL
Raji	NULL
PHA+PMA	NULL
Unstim	NULL
I	NULL
1	NULL
T	NULL
I	NULL
o	NULL
&	NULL
C	NULL
S	NULL
&	NULL
&	NULL
Antiserum	NULL
(	NULL
gé	NULL
\¢	NULL
<	NULL
~°	NULL
,	NULL
\	NULL
yp	NULL
0x6	NULL
}	NULL
\4~	NULL
‘	NULL
°	NULL
,	NULL
\	NULL
r	NULL
©	NULL
©	NULL
&	NULL
GC	NULL
»	NULL
9	NULL
@	NULL
oC	NULL
@	NULL
P	NULL
p	NULL
Fos-Jun	NULL
-	NULL
>	NULL
-	NULL
=	NULL
=	NULL
=	NULL
>	NULL
=-	NULL
#	NULL
0	NULL
#	NULL
0	NULL
#	NULL
+	NULL
awe	NULL
We	NULL
e	NULL
t	NULL
``	NULL
T_	NULL
1°	NULL
2	NULL
3	NULL
4	NULL
50	NULL
6	NULL
7	NULL
8	NULL
Fic	NULL
.	NULL

2	NULL
.	NULL

The	NULL
constitutive	NULL
component	NULL
is	NULL
a	NULL
human	NULL
homologue	NULL
of	NULL
NFATp	NULL
.	NULL

EMSA	NULL
was	NULL
performed	NULL
with	NULL
nuclear	NULL
extracts	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
from	NULL
either	NULL
PHA/PMA-stimulated	NULL
(	NULL
lanes	NULL
1-4	NULL
)	NULL
or	NULL
unstimulated	NULL
(	NULL
lanes	NULL
5-8	NULL
)	NULL
Raji	NULL
cells	NULL
,	NULL
using	NULL
labeled	NULL
human	NULL
IL-2	NULL
NFAT	NULL
oligonucleotide	NULL
as	NULL
a	NULL
probe	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
preimmune	NULL
serum	NULL
,	NULL
antiserum	NULL
against	NULL
recombinant	NULL
murine	NULL
NFATp	NULL
(	NULL
A61	NULL
)	NULL
,	NULL
or	NULL
antiserum	NULL
against	NULL
a	NULL
peptide	NULL
in	NULL
murine	NULL
NFATp	NULL
(	NULL
Ab2	NULL
)	NULL
as	NULL
described	NULL
(	NULL
see	NULL
``	NULL
Experimental	NULL
Procedures	NULL
``	NULL
)	NULL
.	NULL

With	NULL
unstimulated	NULL
nuclear	NULL
extracts	NULL
,	NULL
125	NULL
nM	NULL
Fos/Jun	NULL
heterodimers	NULL
were	NULL
added	NULL
to	NULL
the	NULL
reaction	NULL
mixtures	NULL
for	NULL
NFAT	NULL
reconstitution	NULL
(	NULL
lanes	NULL
5-8	NULL
)	NULL
.	NULL

Since	NULL
antisera	NULL
were	NULL
diluted	NULL
in	NULL
phosphate-buffered	NULL
saline	NULL
,	NULL
1	NULL
wl	NULL
of	NULL
phosphate-buffered	NULL
saline	NULL
was	NULL
added	NULL
to	NULL
the	NULL
control	NULL
reactions	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
5	NULL
)	NULL
.	NULL

Native	NULL
and	NULL
reconstituted	NULL
NFAT	NULL
complexes	NULL
are	NULL
indicated	NULL
by	NULL
an	NULL
arrow	NULL
.	NULL

human	NULL
homologue	NULL
of	NULL
NFATp	NULL
or	NULL
a	NULL
closely	NULL
related	NULL
isoform	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
will	NULL
refer	NULL
to	NULL
the	NULL
component	NULL
as	NULL
human	NULL
NFATp	NULL
.	NULL

CsA	NULL
Alters	NULL
the	NULL
Migration	NULL
of	NULL
Human	NULL
NFATp	NULL
from	NULL
Unstimulated	NULL
Cells	NULL
on	NULL
SDS-polyacrylamide	NULL
gel	NULL
electrophoresis-Using	NULL
an	NULL
antiserum	NULL
against	NULL
recombinant	NULL
murine	NULL
NFATp	NULL
,	NULL
we	NULL
addressed	NULL
the	NULL
question	NULL
,	NULL
raised	NULL
earlier	NULL
,	NULL
of	NULL
whether	NULL
CsA	NULL
treatment	NULL
results	NULL
in	NULL
the	NULL
disappearance	NULL
of	NULL
NFATp	NULL
from	NULL
nuclear	NULL
extracts	NULL
or	NULL
in	NULL
its	NULL
modification	NULL
.	NULL

Equivalent	NULL
amounts	NULL
of	NULL
nuclear	NULL
and	NULL
cytoplasmic	NULL
extracts	NULL
prepared	NULL
in	NULL
equal	NULL
volumes	NULL
from	NULL
CsA-untreated	NULL
or	NULL
-treated	NULL
Raji	NULL
B	NULL
and	NULL
Jurkat	NULL
T	NULL
cell	NULL
lines	NULL
were	NULL
subjected	NULL
to	NULL
electrophoresis	NULL
on	NULL
a	NULL
SDS-polyacrylamide	NULL
gel	NULL
,	NULL
and	NULL
NFATp	NULL
was	NULL
detected	NULL
by	NULL
immunoblot	NULL
analysis	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
.	NULL

Similar	NULL
amounts	NULL
of	NULL
NFATp	NULL
were	NULL
present	NULL
in	NULL
both	NULL
nuclear	NULL
and	NULL
cytoplasmic	NULL
extracts	NULL
with	NULL
no	NULL
significant	NULL
change	NULL
in	NULL
distribution	NULL
after	NULL
CsA	NULL
treatment	NULL
.	NULL

NFATp	NULL
in	NULL
both	NULL
nuclear	NULL
and	NULL
cytoplasmic	NULL
extracts	NULL
of	NULL
untreated	NULL
Raji	NULL
cells	NULL
showed	NULL
a	NULL
diffuse	NULL
band	NULL
pattern	NULL
in	NULL
a	NULL
molecular	NULL
mass	NULL
range	NULL
of	NULL
116-130	NULL
kDa	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
,	NULL
whereas	NULL
that	NULL
of	NULL
CsA-treated	NULL
Raji	NULL
cells	NULL
displayed	NULL
one	NULL
major	NULL
band	NULL
with	NULL
an	NULL
apparent	NULL
molecular	NULL
mass	NULL
of	NULL
~130	NULL
kDa	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
.	NULL

In	NULL
Jurkat	NULL
T	NULL
cells	NULL
,	NULL
NFATp	NULL
from	NULL
untreated	NULL
cells	NULL
migrated	NULL
slightly	NULL
faster	NULL
than	NULL
that	NULL
seen	NULL
in	NULL
CsA-treated	NULL
cells	NULL
and	NULL
did	NULL
not	NULL
show	NULL
a	NULL
diffuse	NULL
band	NULL
pattern	NULL
.	NULL

It	NULL
thus	NULL
appears	NULL
that	NULL
,	NULL
in	NULL
these	NULL
cell	NULL
Mechanism	NULL
for	NULL
Cyclosporin	NULL
A	NULL
Inhibition	NULL
of	NULL
NFAT	NULL
B	NULL
Raji	NULL
Jurkat	NULL
A	NULL
Raji	NULL
Jurial	NULL
CsA	NULL
ie	NULL
+	NULL
a	NULL
F	NULL
II	NULL
[	NULL
I	NULL
CsA	NULL
®	NULL
-	NULL
_	NULL
_+	NULL
_	NULL
_-	NULL
+	NULL
N	NULL
C	NULL
N	NULL
C	NULL
N	NULL
C	NULL
N	NULL
C	NULL
5910	NULL
1F	NULL
1F	NULL
13	NULL
N	NULL
C	NULL
N	NULL
C	NULL
N	NULL
C	NULL
N	NULL
C	NULL
-200	NULL
USF	NULL
-	NULL
»	NULL
--	NULL
--	NULL
_	NULL
as	NULL
an	NULL
._	NULL
(	NULL
43	NULL
,	NULL
44	NULL
kDa	NULL
)	NULL
o	NULL
Anco	NULL
-116	NULL
LDH	NULL
-	NULL
#	NULL
#	NULL
ad	NULL
«	NULL
--	NULL
ame	NULL
had	NULL
«	NULL
p	NULL
-	NULL
a	NULL
»	NULL
-	NULL
85	NULL
(	NULL
35	NULL
kDa	NULL
)	NULL
102	NULL
s	NULL
40	NULL
50	NULL
607	NULL
B	NULL
102	NULL
3	NULL
4	NULL
50	NULL
60	NULL
7	NULL
8	NULL
Fic	NULL
.	NULL

3	NULL
.	NULL

Effect	NULL
of	NULL
CsA	NULL
on	NULL
posttranslational	NULL
modification	NULL
of	NULL
NFATp	NULL
.	NULL

A	NULL
,	NULL
immunoblot	NULL
analysis	NULL
of	NULL
NFATp	NULL
was	NULL
performed	NULL
with	NULL
both	NULL
nuclear	NULL
and	NULL
cytoplasmic	NULL
extracts	NULL
.	NULL

Nuclear	NULL
and	NULL
ammonium	NULL
sulfate-pre-cipitated	NULL
cytoplasmic	NULL
proteins	NULL
were	NULL
prepared	NULL
in	NULL
equal	NULL
volumes	NULL
from	NULL
Raji	NULL
and	NULL
Jurkat	NULL
cells	NULL
either	NULL
untreated	NULL
or	NULL
treated	NULL
with	NULL
1	NULL
ug/ml	NULL
CsA	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
.	NULL
``	NULL

Equal	NULL
volumes	NULL
of	NULL
nuclear	NULL
(	NULL
N	NULL
)	NULL
and	NULL
cytoplasmic	NULL
(	NULL
C	NULL
)	NULL
extracts	NULL
were	NULL
separated	NULL
on	NULL
7	NULL
%	NULL
SDS-polyacrylamide	NULL
gels	NULL
,	NULL
transferred	NULL
on	NULL
nitrocellulose	NULL
membranes	NULL
,	NULL
and	NULL
immuno-blotted	NULL
for	NULL
NFATp	NULL
with	NULL
an	NULL
antiserum	NULL
to	NULL
recombinant	NULL
murine	NULL
NFATp	NULL
.	NULL

The	NULL
amounts	NULL
of	NULL
proteins	NULL
loaded	NULL
on	NULL
each	NULL
lane	NULL
were	NULL
as	NULL
follows	NULL
:	NULL
lane	NULL
1	NULL
,	NULL
30	NULL
ug	NULL
;	NULL
lane	NULL
2	NULL
,	NULL
71	NULL
ug	NULL
;	NULL
lane	NULL
3	NULL
,	NULL
31	NULL
ug	NULL
;	NULL
lane	NULL
4	NULL
,	NULL
100	NULL
ug	NULL
;	NULL
lane	NULL
5	NULL
,	NULL
30	NULL
ug	NULL
;	NULL
lane	NULL
6	NULL
,	NULL
47	NULL
ug	NULL
;	NULL
lane	NULL
7	NULL
,	NULL
28	NULL
ug	NULL
;	NULL
lane	NULL
8	NULL
,	NULL
39	NULL
ug	NULL
.	NULL

Arrows	NULL
indicate	NULL
NFAT	NULL
p	NULL
,	NULL
and	NULL
molecular	NULL
mass	NULL
standards	NULL
(	NULL
in	NULL
kDa	NULL
)	NULL
are	NULL
marked	NULL
at	NULL
the	NULL
right	NULL
.	NULL

B	NULL
,	NULL
immunoblot	NULL
analyses	NULL
performed	NULL
with	NULL
antibodies	NULL
raised	NULL
against	NULL
a	NULL
nuclear	NULL
protein	NULL
(	NULL
USF	NULL
)	NULL
and	NULL
a	NULL
cytoplasmic	NULL
protein	NULL
(	NULL
LDH	NULL
)	NULL
demonstrate	NULL
absence	NULL
of	NULL
significant	NULL
contamination	NULL
of	NULL
nuclear	NULL
extracts	NULL
with	NULL
cytoplasmic	NULL
proteins	NULL
.	NULL

Equal	NULL
volumes	NULL
of	NULL
the	NULL
nuclear	NULL
(	NULL
N	NULL
)	NULL
and	NULL
cytoplasmic	NULL
(	NULL
C	NULL
)	NULL
extracts	NULL
used	NULL
in	NULL
panel	NULL
A	NULL
were	NULL
separated	NULL
on	NULL
a	NULL
10	NULL
%	NULL
SDS-polyacrylamide	NULL
gel	NULL
and	NULL
analyzed	NULL
in	NULL
immunoblot	NULL
assays	NULL
using	NULL
either	NULL
anti-USF	NULL
antibody	NULL
(	NULL
top	NULL
)	NULL
or	NULL
anti-LDH	NULL
antibody	NULL
(	NULL
bottom	NULL
)	NULL
.	NULL

lines	NULL
,	NULL
CsA	NULL
alters	NULL
the	NULL
migration	NULL
of	NULL
NFATp	NULL
on	NULL
a	NULL
SDS-polyacrylamide	NULL
gel	NULL
but	NULL
does	NULL
not	NULL
affect	NULL
its	NULL
subcellular	NULL
distribution	NULL
.	NULL

A	NULL
band	NULL
migrating	NULL
at	NULL
~85	NULL
kDa	NULL
is	NULL
strongly	NULL
recognized	NULL
by	NULL
the	NULL
antibody	NULL
in	NULL
cytoplasmic	NULL
extracts	NULL
of	NULL
Raji	NULL
B	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

34	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
4	NULL
)	NULL
.	NULL

The	NULL
migration	NULL
of	NULL
this	NULL
band	NULL
is	NULL
not	NULL
altered	NULL
by	NULL
CsA	NULL
treatment	NULL
,	NULL
and	NULL
its	NULL
nature	NULL
is	NULL
currently	NULL
unclear	NULL
.	NULL

Since	NULL
NFATp	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
be	NULL
mainly	NULL
a	NULL
cytoplasmic	NULL
protein	NULL
in	NULL
unstimulated	NULL
murine	NULL
T	NULL
cells	NULL
(	NULL
McCaffrey	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993a	NULL
)	NULL
,	NULL
it	NULL
was	NULL
important	NULL
to	NULL
rule	NULL
out	NULL
significant	NULL
contamination	NULL
of	NULL
nuclear	NULL
extracts	NULL
with	NULL
cytoplasmic	NULL
proteins	NULL
.	NULL

Nuclear	NULL
and	NULL
cytoplasmic	NULL
extracts	NULL
prepared	NULL
by	NULL
the	NULL
same	NULL
method	NULL
were	NULL
tested	NULL
in	NULL
immunoblot	NULL
analyses	NULL
with	NULL
antibodies	NULL
against	NULL
a	NULL
cytoplasmic	NULL
protein	NULL
marker	NULL
,	NULL
the	NULL
LDH	NULL
(	NULL
Cahn	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1962	NULL
)	NULL
,	NULL
or	NULL
to	NULL
a	NULL
nuclear	NULL
protein	NULL
marker	NULL
,	NULL
USF	NULL
.	NULL

The	NULL
USF	NULL
transcription	NULL
factor	NULL
,	NULL
composed	NULL
of	NULL
43-	NULL
and	NULL
44-kDa	NULL
polypeptides	NULL
,	NULL
is	NULL
a	NULL
member	NULL
of	NULL
the	NULL
basic	NULL
,	NULL
helix-loop-helix	NULL
family	NULL
and	NULL
localized	NULL
predominantly	NULL
in	NULL
the	NULL
nucleus	NULL
(	NULL
Sawadogo	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
;	NULL
Pognonec	NULL
and	NULL
Roeder	NULL
,	NULL
1991	NULL
)	NULL
.	NULL

The	NULL
majority	NULL
of	NULL
USF	NULL
was	NULL
detected	NULL
in	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
both	NULL
B	NULL
and	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
,	NULL
top	NULL
)	NULL
,	NULL
whereas	NULL
LDH	NULL
was	NULL
mainly	NULL
observed	NULL
in	NULL
cytoplasmic	NULL
extracts	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
,	NULL
bottom	NULL
)	NULL
.	NULL

These	NULL
data	NULL
rule	NULL
out	NULL
any	NULL
significant	NULL
contamination	NULL
of	NULL
nuclear	NULL
extracts	NULL
with	NULL
cytoplasmic	NULL
proteins	NULL
.	NULL

CsA-mediated	NULL
Phosphorylation	NULL
of	NULL
NFAT	NULL
p	NULL
in	NULL
Raji	NULL
and	NULL
Jurkat	NULL
Cells-To	NULL
test	NULL
whether	NULL
the	NULL
migration	NULL
shift	NULL
after	NULL
CsA	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
is	NULL
due	NULL
to	NULL
phosphorylation	NULL
of	NULL
NFATp	NULL
,	NULL
nuclear	NULL
extracts	NULL
were	NULL
treated	NULL
with	NULL
calf	NULL
intestinal	NULL
AP	NULL
or	NULL
CaN	NULL
in	NULL
vitro	NULL
and	NULL
analyzed	NULL
by	NULL
immunoblot	NULL
assays	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
NFATp	NULL
migrated	NULL
at	NULL
a	NULL
higher	NULL
apparent	NULL
molecular	NULL
mass	NULL
in	NULL
nuclear	NULL
extracts	NULL
from	NULL
CsA-treated	NULL
Raji	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

44	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
NFATp	NULL
in	NULL
CsA-treated	NULL
cells	NULL
migrated	NULL
faster	NULL
after	NULL
AP	NULL
treatment	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
,	NULL
and	NULL
CaN	NULL
treatment	NULL
increased	NULL
the	NULL
migration	NULL
to	NULL
that	NULL
observed	NULL
in	NULL
the	NULL
untreated	NULL
cells	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

Migration	NULL
of	NULL
NFAT	NULL
p	NULL
in	NULL
CsA-untreated	NULL
Raji	NULL
cells	NULL
was	NULL
not	NULL
significantly	NULL
changed	NULL
by	NULL
either	NULL
one	NULL
of	NULL
the	NULL
phosphatase	NULL
treatments	NULL
(	NULL
lanes	NULL
1-3	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
the	NULL
apparent	NULL
molecular	NULL
mass	NULL
of	NULL
NFAT	NULL
p	NULL
in	NULL
Mechanism	NULL
for	NULL
Cyclosporin	NULL
A	NULL
Inhibition	NULL
of	NULL
NFAT	NULL
A	NULL
B	NULL
Raji	NULL
Jurkat	NULL
-CsA	NULL
+CsA	NULL
5	NULL
-CsA	NULL
+CsA	NULL
z	NULL
A	NULL
7	NULL
7	NULL
8	NULL
3	NULL
-	NULL
%	NULL
a	NULL
%	NULL
a	NULL
%	NULL
&	NULL
2	NULL
®	NULL
a	NULL
%	NULL
a	NULL
&	NULL
&	NULL
%	NULL
<	NULL
o	NULL
<	NULL
0	NULL
<	NULL
E	NULL
I	NULL
<	NULL
o	NULL
<	NULL
o	NULL
<	NULL
o	NULL
-	NULL
200	NULL
-	NULL
§§	NULL
1or	NULL
s	NULL
40	NULL
50	NULL
60	NULL
f	NULL
s	NULL
9	NULL
102	NULL
s	NULL
4	NULL
5	NULL
60	NULL
Tos	NULL
D	NULL
+	NULL
CsA	NULL
c	NULL
g	NULL
CaN	NULL
AP	NULL
Immunoblot	NULL
Phosphorimager	NULL
Y	NULL
(	NULL
w	NULL
s	NULL
see	NULL
-_	NULL
]	NULL
-	NULL
CsA	NULL
+	NULL
CsA	NULL
-	NULL
CsA	NULL
+	NULL
CsA	NULL
|-	NULL
200	NULL
§	NULL
%	NULL
-_-	NULL
$	NULL
-_-	NULL
5	NULL
~	NULL
@	NULL
we	NULL
«	NULL
=	NULL
ina	NULL
Etﬂ	NULL
Toe	NULL
mae	NULL
water	NULL
.-	NULL
.	NULL

'-	NULL
“	NULL
s	NULL
o	NULL
>	NULL
>	NULL
x	NULL
wit	NULL
7	NULL
a	NULL
®	NULL
>	NULL
H	NULL
85	NULL
10203	NULL
a	NULL
00506	NULL
1	NULL
r	NULL
s	NULL
4	NULL
s	NULL
6	NULL
T	NULL
s	NULL
s	NULL
10	NULL
i	NULL
Fic	NULL
.	NULL

4	NULL
.	NULL

In	NULL
vitro	NULL
dephosphorylation	NULL
of	NULL
NFATp	NULL
by	NULL
calf	NULL
intestinal	NULL
AP	NULL
and	NULL
CaN	NULL
.	NULL

A	NULL
and	NULL
B	NULL
,	NULL
nuclear	NULL
extracts	NULL
(	NULL
40	NULL
ug	NULL
)	NULL
from	NULL
either	NULL
CsA-untreated	NULL
(	NULL
lanes	NULL
1-3	NULL
)	NULL
or	NULL
treated	NULL
(	NULL
lanes	NULL
4-8	NULL
)	NULL
Raji	NULL
and	NULL
Jurkat	NULL
cells	NULL
were	NULL
incubated	NULL
either	NULL
alone	NULL
or	NULL
with	NULL
AP	NULL
or	NULL
CaN	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
phosphatase	NULL
inhibitors	NULL
(	NULL
/	NULL
)	NULL
consisting	NULL
of	NULL
20	NULL
mM	NULL
sodium	NULL
pyrophosphate	NULL
and	NULL
50	NULL
mM	NULL
NaF	NULL
,	NULL
and	NULL
analyzed	NULL
in	NULL
immunoblot	NULL
assays	NULL
using	NULL
an	NULL
antiserum	NULL
to	NULL
recombinant	NULL
murine	NULL
NFATp	NULL
.	NULL

Lane	NULL
8	NULL
in	NULL
panel	NULL
A	NULL
is	NULL
heat-inactivated	NULL
CaN	NULL
,	NULL
and	NULL
lane	NULL
9	NULL
in	NULL
panel	NULL
A	NULL
is	NULL
nuclear	NULL
extract	NULL
of	NULL
HeLa	NULL
cells	NULL
.	NULL

NFATp	NULL
is	NULL
indicated	NULL
by	NULL
arrows	NULL
.	NULL

C	NULL
,	NULL
immunoprecipitation	NULL
of	NULL
NFATp	NULL
from	NULL
nuclear	NULL
extracts	NULL
of	NULL
metabolically	NULL
*°P-labeled	NULL
Raji	NULL
cells	NULL
.	NULL

Raji	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
or	NULL
without	NULL
1	NULL
ug/ml	NULL
CsA	NULL
for	NULL
2	NULL
h	NULL
in	NULL
medium	NULL
containing	NULL
[	NULL
*P	NULL
Jorthophosphate	NULL
,	NULL
and	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
.	NULL
``	NULL

Nuclear	NULL
extracts	NULL
(	NULL
300	NULL
ug	NULL
)	NULL
from	NULL
CsA-treated	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
CaN	NULL
.	NULL

NFATp	NULL
was	NULL
immunoprecipitated	NULL
with	NULL
R59	NULL
antiserum	NULL
from	NULL
nuclear	NULL
extracts	NULL
and	NULL
analyzed	NULL
in	NULL
an	NULL
immunoblot	NULL
assay	NULL
(	NULL
left	NULL
panel	NULL
)	NULL
.	NULL

The	NULL
same	NULL
membrane	NULL
was	NULL
scanned	NULL
by	NULL
a	NULL
PhosphorImager	NULL
(	NULL
right	NULL
panel	NULL
)	NULL
.	NULL

Filled	NULL
arrow	NULL
indicates	NULL
phosphorylated	NULL
NFATp	NULL
,	NULL
and	NULL
open	NULL
arrow	NULL
indicates	NULL
dephosphorylated	NULL
form	NULL
.	NULL

D	NULL
,	NULL
nuclear	NULL
extracts	NULL
(	NULL
40	NULL
ug	NULL
)	NULL
from	NULL
CsA-treated	NULL
Raji	NULL
cells	NULL
were	NULL
incubated	NULL
either	NULL
alone	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
7	NULL
)	NULL
or	NULL
with	NULL
increasing	NULL
amounts	NULL
of	NULL
CaN	NULL
(	NULL
lanes	NULL
3-6	NULL
)	NULL
or	NULL
AP	NULL
(	NULL
lanes	NULL
8-11	NULL
)	NULL
,	NULL
and	NULL
analyzed	NULL
in	NULL
an	NULL
immunoblot	NULL
assay	NULL
.	NULL

Lane	NULL
1	NULL
is	NULL
CsA-untreated	NULL
.	NULL

The	NULL
amounts	NULL
of	NULL
CaN	NULL
used	NULL
in	NULL
each	NULL
lane	NULL
were	NULL
as	NULL
follows	NULL
:	NULL
lane	NULL
3	NULL
,	NULL
0.06	NULL
ug	NULL
;	NULL
lane	NULL
4	NULL
,	NULL
0.12	NULL
ug	NULL
;	NULL
lane	NULL
5	NULL
,	NULL
0.25	NULL
ug	NULL
;	NULL
lane	NULL
6	NULL
,	NULL
0.50	NULL
ug	NULL
.	NULL

Those	NULL
of	NULL
AP	NULL
were	NULL
as	NULL
follows	NULL
:	NULL
lane	NULL
8	NULL
,	NULL
1.4	NULL
units	NULL
;	NULL
lane	NULL
9	NULL
,	NULL
2.8	NULL
units	NULL
;	NULL
lane	NULL
10	NULL
,	NULL
5.6	NULL
units	NULL
;	NULL
lane	NULL
11	NULL
,	NULL
11.2	NULL
units	NULL
.	NULL

NFATp	NULL
is	NULL
indicated	NULL
by	NULL
arrows	NULL
.	NULL

CsA-untreated	NULL
Jurkat	NULL
cells	NULL
was	NULL
decreased	NULL
by	NULL
AP	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
and	NULL
further	NULL
by	NULL
CaN	NULL
to	NULL
the	NULL
level	NULL
of	NULL
that	NULL
of	NULL
CsA-untreated	NULL
Raji	NULL
cells	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

NFATp	NULL
in	NULL
CsA-treated	NULL
Jurkat	NULL
cells	NULL
showed	NULL
similar	NULL
changes	NULL
to	NULL
those	NULL
of	NULL
CsA-untreated	NULL
cells	NULL
by	NULL
AP	NULL
or	NULL
CaN	NULL
treatments	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
.	NULL

These	NULL
migration	NULL
changes	NULL
were	NULL
blocked	NULL
by	NULL
general	NULL
phosphatase	NULL
inhibitors	NULL
such	NULL
as	NULL
sodium	NULL
pyrophosphate	NULL
and	NULL
NaF	NULL
(	NULL
Fig	NULL
.	NULL

44	NULL
,	NULL
lane	NULL
7	NULL
,	NULL
and	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
)	NULL
and	NULL
by	NULL
heat	NULL
inactivation	NULL
of	NULL
CaN	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
,	NULL
lane	NULL
8	NULL
)	NULL
,	NULL
strongly	NULL
suggesting	NULL
that	NULL
they	NULL
resulted	NULL
from	NULL
dephosphorylation	NULL
of	NULL
NFATp	NULL
.	NULL

NFATp	NULL
was	NULL
not	NULL
detected	NULL
in	NULL
HeLa	NULL
cell	NULL
nuclear	NULL
extracts	NULL
(	NULL
Fig	NULL
.	NULL

44	NULL
,	NULL
lane	NULL
9	NULL
)	NULL
,	NULL
consistent	NULL
with	NULL
absence	NULL
of	NULL
NFAT	NULL
induction	NULL
and	NULL
its	NULL
transactivation	NULL
function	NULL
in	NULL
HeLa	NULL
cells	NULL
(	NULL
Shaw	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
.	NULL

To	NULL
further	NULL
confirm	NULL
that	NULL
the	NULL
migration	NULL
shifts	NULL
observed	NULL
with	NULL
CsA	NULL
and	NULL
CaN	NULL
treatments	NULL
are	NULL
indeed	NULL
due	NULL
to	NULL
changes	NULL
in	NULL
the	NULL
phosphorylation	NULL
level	NULL
of	NULL
NFATp	NULL
,	NULL
Raji	NULL
cells	NULL
were	NULL
metabolically	NULL
labeled	NULL
with	NULL
[	NULL
*P	NULL
Jorthophosphate	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
CsA	NULL
treatment	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
treated	NULL
with	NULL
or	NULL
without	NULL
20657	NULL
CaN	NULL
,	NULL
and	NULL
NFATp	NULL
was	NULL
immunoprecipitated	NULL
,	NULL
separated	NULL
on	NULL
SDS-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
,	NULL
and	NULL
transferred	NULL
to	NULL
nitrocellulose	NULL
membrane	NULL
(	NULL
Fig	NULL
.	NULL

4C	NULL
)	NULL
.	NULL

Immunoblotting	NULL
with	NULL
NFATp	NULL
antibody	NULL
confirmed	NULL
the	NULL
migration	NULL
shift	NULL
and	NULL
the	NULL
presence	NULL
of	NULL
similar	NULL
amounts	NULL
of	NULL
NFATp	NULL
in	NULL
the	NULL
different	NULL
samples	NULL
(	NULL
Fig	NULL
.	NULL

4C	NULL
,	NULL
left	NULL
panel	NULL
)	NULL
.	NULL

PhosphorImager	NULL
scan	NULL
of	NULL
the	NULL
same	NULL
membrane	NULL
showed	NULL
that	NULL
CsA	NULL
treatment	NULL
resulted	NULL
in	NULL
an	NULL
increased	NULL
level	NULL
of	NULL
phosphorylation	NULL
of	NULL
NFATp	NULL
and	NULL
that	NULL
the	NULL
phosphorylation	NULL
level	NULL
returned	NULL
to	NULL
base	NULL
line	NULL
after	NULL
CaN	NULL
treatment	NULL
of	NULL
nuclear	NULL
extract	NULL
(	NULL
Fig	NULL
.	NULL

4C	NULL
,	NULL
right	NULL
panel	NULL
)	NULL
.	NULL

These	NULL
data	NULL
confirm	NULL
that	NULL
NFATp	NULL
migration	NULL
shifts	NULL
in	NULL
response	NULL
to	NULL
CsA	NULL
and	NULL
phosphatase	NULL
treatments	NULL
are	NULL
accompanied	NULL
by	NULL
appropriate	NULL
shifts	NULL
in	NULL
its	NULL
phosphorylation	NULL
level	NULL
.	NULL

The	NULL
smaller	NULL
migration	NULL
shift	NULL
after	NULL
AP	NULL
treatment	NULL
suggests	NULL
that	NULL
AP	NULL
dephosphorylates	NULL
fewer	NULL
sites	NULL
than	NULL
CaN	NULL
.	NULL

Furthermore	NULL
,	NULL
comigration	NULL
of	NULL
Jurkat	NULL
and	NULL
Raji	NULL
NFATp	NULL
after	NULL
CaN	NULL
treatment	NULL
suggests	NULL
that	NULL
NFATp	NULL
in	NULL
Jurkat	NULL
cells	NULL
may	NULL
be	NULL
identical	NULL
to	NULL
that	NULL
of	NULL
Raji	NULL
cells	NULL
and	NULL
that	NULL
the	NULL
difference	NULL
in	NULL
migration	NULL
observed	NULL
without	NULL
phosphatase	NULL
treatments	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
5	NULL
)	NULL
was	NULL
due	NULL
either	NULL
to	NULL
different	NULL
degrees	NULL
of	NULL
phosphorylation	NULL
of	NULL
NFATp	NULL
in	NULL
B	NULL
versus	NULL
T	NULL
cells	NULL
or	NULL
to	NULL
differential	NULL
nonspecific	NULL
phosphatase	NULL
activity	NULL
during	NULL
extract	NULL
preparation	NULL
.	NULL

To	NULL
exclude	NULL
the	NULL
possibility	NULL
that	NULL
the	NULL
differential	NULL
effects	NULL
of	NULL
AP	NULL
and	NULL
CaN	NULL
on	NULL
NFATp	NULL
migration	NULL
are	NULL
due	NULL
to	NULL
less	NULL
than	NULL
optimal	NULL
enzyme	NULL
concentrations	NULL
,	NULL
nuclear	NULL
extracts	NULL
from	NULL
CsA-treated	NULL
Raji	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
increasing	NULL
amounts	NULL
of	NULL
CaN	NULL
or	NULL
AP	NULL
and	NULL
analyzed	NULL
in	NULL
an	NULL
immunoblot	NULL
assay	NULL
(	NULL
Fig	NULL
.	NULL

4D	NULL
)	NULL
.	NULL

The	NULL
faster	NULL
migrating	NULL
form	NULL
of	NULL
NFAT	NULL
p	NULL
began	NULL
to	NULL
appear	NULL
at	NULL
0.12	NULL
ug	NULL
of	NULL
CaN	NULL
treatment	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
and	NULL
at	NULL
0.25	NULL
ug	NULL
of	NULL
CaN	NULL
all	NULL
NFATp	NULL
became	NULL
faster	NULL
migrating	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
;	NULL
further	NULL
migration	NULL
shift	NULL
was	NULL
not	NULL
even	NULL
observed	NULL
up	NULL
to	NULL
2	NULL
ug	NULL
of	NULL
CaN	NULL
treatment	NULL
as	NULL
shown	NULL
earlier	NULL
in	NULL
Fig	NULL
.	NULL

4A	NULL
.	NULL

Similarly	NULL
,	NULL
NFATp	NULL
migration	NULL
was	NULL
faster	NULL
,	NULL
but	NULL
not	NULL
as	NULL
much	NULL
as	NULL
that	NULL
of	NULL
CaN	NULL
treatment	NULL
,	NULL
at	NULL
1	NULL
unit	NULL
of	NULL
AP	NULL
,	NULL
and	NULL
a	NULL
higher	NULL
concentration	NULL
of	NULL
AP	NULL
up	NULL
to	NULL
12	NULL
units	NULL
did	NULL
not	NULL
generate	NULL
further	NULL
migration	NULL
shift	NULL
.	NULL

Thus	NULL
,	NULL
a	NULL
smaller	NULL
migration	NULL
shift	NULL
observed	NULL
with	NULL
AP	NULL
as	NULL
compared	NULL
with	NULL
that	NULL
observed	NULL
with	NULL
CaN	NULL
is	NULL
not	NULL
due	NULL
to	NULL
suboptimal	NULL
enzyme	NULL
concentration	NULL
and	NULL
is	NULL
most	NULL
likely	NULL
due	NULL
to	NULL
dephosphorylation	NULL
of	NULL
fewer	NULL
sites	NULL
.	NULL

Dephosphorylation	NULL
of	NULL
NFATp	NULL
after	NULL
CsA	NULL
Treatment	NULL
Restores	NULL
Its	NULL
Ability	NULL
to	NULL
Form	NULL
an	NULL
NFAT	NULL
Complex-To	NULL
examine	NULL
whether	NULL
dephosphorylation	NULL
of	NULL
NFAT	NULL
p	NULL
restores	NULL
NFAT	NULL
binding	NULL
activity	NULL
in	NULL
CsA-treated	NULL
Raji	NULL
B	NULL
and	NULL
Jurkat	NULL
T	NULL
cells	NULL
,	NULL
nuclear	NULL
extracts	NULL
from	NULL
CsA-treated	NULL
cells	NULL
were	NULL
exposed	NULL
in	NULL
vitro	NULL
to	NULL
either	NULL
AP	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
)	NULL
or	NULL
CaN	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
.	NULL

These	NULL
extracts	NULL
were	NULL
then	NULL
compared	NULL
by	NULL
EMSA	NULL
with	NULL
untreated	NULL
nuclear	NULL
extracts	NULL
for	NULL
their	NULL
ability	NULL
to	NULL
form	NULL
NFAT	NULL
complexes	NULL
in	NULL
cooperation	NULL
with	NULL
Fos/Jun	NULL
dimers	NULL
.	NULL

NFAT	NULL
reconstitution	NULL
in	NULL
CsA-untreated	NULL
Raji	NULL
and	NULL
Jurkat	NULL
cells	NULL
was	NULL
not	NULL
significantly	NULL
influenced	NULL
by	NULL
AP	NULL
or	NULL
CaN	NULL
treatment	NULL
(	NULL
compare	NULL
lane	NULL
6	NULL
with	NULL
lane	NULL
2	NULL
in	NULL
each	NULL
panel	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
inhibition	NULL
of	NULL
NFAT	NULL
reconstitution	NULL
in	NULL
CsA-treated	NULL
cells	NULL
was	NULL
completely	NULL
reversed	NULL
by	NULL
either	NULL
one	NULL
of	NULL
the	NULL
phosphatase	NULL
treatments	NULL
(	NULL
compare	NULL
lane	NULL
8	NULL
with	NULL
lane	NULL
4	NULL
in	NULL
each	NULL
panel	NULL
)	NULL
,	NULL
and	NULL
the	NULL
restoration	NULL
was	NULL
blocked	NULL
by	NULL
sodium	NULL
pyrophosphate	NULL
and	NULL
NaF	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
lane	NULL
9	NULL
)	NULL
.	NULL

The	NULL
restored	NULL
NFAT	NULL
complexes	NULL
had	NULL
the	NULL
same	NULL
DNA-binding	NULL
specificity	NULL
as	NULL
those	NULL
from	NULL
CsA-untreated	NULL
cells	NULL
,	NULL
as	NULL
assessed	NULL
by	NULL
competition	NULL
tests	NULL
with	NULL
specific	NULL
and	NULL
nonspecific	NULL
competitors	NULL
and	NULL
supershifts	NULL
with	NULL
antisera	NULL
to	NULL
murine	NULL
NFAT	NULL
p	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
demonstrate	NULL
that	NULL
dephosphorylation	NULL
of	NULL
NFATp	NULL
is	NULL
essential	NULL
for	NULL
NFAT	NULL
complex	NULL
assembly	NULL
in	NULL
cooperation	NULL
with	NULL
Fos	NULL
and	NULL
Jun	NULL
proteins	NULL
.	NULL

More-over	NULL
,	NULL
partial	NULL
dephosphorylation	NULL
mediated	NULL
by	NULL
AP	NULL
is	NULL
sufficient	NULL
to	NULL
restore	NULL
the	NULL
ability	NULL
of	NULL
nuclear	NULL
extracts	NULL
to	NULL
participate	NULL
in	NULL
NFAT	NULL
complex	NULL
assembly	NULL
.	NULL

Minor	NULL
migration	NULL
differences	NULL
observed	NULL
in	NULL
NFAT	NULL
complexes	NULL
restored	NULL
by	NULL
phosphatase	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

54	NULL
,	NULL
top	NULL
panel	NULL
,	NULL
compare	NULL
lane	NULL
2	NULL
with	NULL
lane	NULL
8	NULL
,	NULL
and	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
bottom	NULL
panel	NULL
,	NULL
compare	NULL
lane	NULL
2	NULL
with	NULL
lanes	NULL
6	NULL
and	NULL
8	NULL
)	NULL
are	NULL
probably	NULL
due	NULL
to	NULL
differing	NULL
degrees	NULL
of	NULL
dephosphorylation	NULL
of	NULL
NFATp	NULL
under	NULL
the	NULL
conditions	NULL
indicated	NULL
,	NULL
which	NULL
also	NULL
resulted	NULL
in	NULL
different	NULL
migrations	NULL
on	NULL
SDS-polyacrylamide	NULL
gels	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

A	NULL
B	NULL
-CsA	NULL
_	NULL
+GsA	NULL
_	NULL
CsA	NULL
+CsA	NULL
-CsA	NULL
_	NULL
+GsA	NULL
_	NULL
CsA	NULL
+CsA	NULL
-A-	NULL
--	NULL
f-	NULL
4	NULL
fo-3	NULL
AP	NULL
-o	NULL
6	NULL
4	NULL
4+	NULL
4+	NULL
o+	NULL
%	NULL
CaN	NULL
L	NULL
.	NULL

-	NULL
0	NULL
.	NULL

4	NULL
4	NULL
+	NULL
4	NULL
+7	NULL
Fosiun	NULL
$	NULL
.	NULL

ion	NULL
ip	NULL
n	NULL
%	NULL
Foslun	NULL
-	NULL
&	NULL
-	NULL
4g	NULL
-	NULL
og	NULL
-	NULL
40+	NULL
.	NULL

.	NULL

Rajl	NULL
*	NULL
'	NULL
'	NULL
'	NULL
Rajl	NULL
\	NULL
.	NULL

u	NULL
ae	NULL
we	NULL
Jurkat	NULL
Y	NULL
.	NULL

1	NULL
&	NULL
@	NULL
_J	NULL
J	NULL
Fic	NULL
.	NULL

5	NULL
.	NULL

Dephosphorylation	NULL
of	NULL
NFATp	NULL
restores	NULL
reconstitution	NULL
of	NULL
NFAT	NULL
complex	NULL
in	NULL
nuclear	NULL
extracts	NULL
from	NULL
CsA-treated	NULL
cells	NULL
.	NULL

A	NULL
,	NULL
nuclear	NULL
extracts	NULL
from	NULL
CsA-untreated	NULL
or	NULL
treated	NULL
Raji	NULL
(	NULL
fop	NULL
panel	NULL
)	NULL
and	NULL
Jurkat	NULL
(	NULL
bottom	NULL
panel	NULL
)	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
(	NULL
lanes	NULL
5-8	NULL
)	NULL
or	NULL
without	NULL
(	NULL
lanes	NULL
1-4	NULL
)	NULL
AP	NULL
,	NULL
and	NULL
subsequently	NULL
tested	NULL
for	NULL
DNA-binding	NULL
to	NULL
a	NULL
human	NULL
IL-2	NULL
NFAT	NULL
oligonucleotide	NULL
in	NULL
the	NULL
presence	NULL
(	NULL
even	NULL
numbered	NULL
lanes	NULL
)	NULL
or	NULL
absence	NULL
(	NULL
odd	NULL
numbered	NULL
lanes	NULL
)	NULL
of	NULL
Fos/Jun	NULL
heterodimers	NULL
.	NULL

B	NULL
,	NULL
same	NULL
experiment	NULL
as	NULL
in	NULL
A	NULL
but	NULL
with	NULL
CaN	NULL
instead	NULL
of	NULL
AP	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
CaN	NULL
,	NULL
50	NULL
mM	NULL
NaF	NULL
and	NULL
20	NULL
mm	NULL
sodium	NULL
pyrophosphate	NULL
were	NULL
added	NULL
to	NULL
the	NULL
reaction	NULL
mixture	NULL
to	NULL
inhibit	NULL
CaN	NULL
phosphatase	NULL
activity	NULL
in	NULL
lane	NULL
9	NULL
,	NULL
bottom	NULL
panel	NULL
.	NULL

Reconstituted	NULL
NFAT	NULL
complexes	NULL
are	NULL
indicated	NULL
by	NULL
an	NULL
arrow	NULL
.	NULL

The	NULL
faint	NULL
band	NULL
observed	NULL
under	NULL
the	NULL
reconstituted	NULL
NFAT	NULL
complex	NULL
represents	NULL
weak	NULL
direct	NULL
binding	NULL
of	NULL
Fos/Jun	NULL
heterodimers	NULL
to	NULL
the	NULL
human	NULL
IL-2	NULL
NFAT	NULL
site	NULL
(	NULL
Yaseen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

Dephosphorylation	NULL
of	NULL
NFAT	NULL
p	NULL
Is	NULL
Required	NULL
for	NULL
DNA	NULL
Binding-Failure	NULL
of	NULL
the	NULL
phosphorylated	NULL
form	NULL
of	NULL
NFAT	NULL
p	NULL
to	NULL
form	NULL
NFAT	NULL
complexes	NULL
could	NULL
be	NULL
due	NULL
to	NULL
either	NULL
inability	NULL
to	NULL
bind	NULL
to	NULL
DNA	NULL
or	NULL
inability	NULL
to	NULL
interact	NULL
with	NULL
Fos/Jun	NULL
dimers	NULL
or	NULL
both	NULL
.	NULL

Since	NULL
NFATp	NULL
is	NULL
able	NULL
to	NULL
bind	NULL
directly	NULL
to	NULL
the	NULL
murine	NULL
IL-2	NULL
NFAT	NULL
motif	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
Fos	NULL
and	NULL
Jun	NULL
proteins	NULL
(	NULL
Jain	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
,	NULL
we	NULL
tested	NULL
whether	NULL
the	NULL
effect	NULL
of	NULL
CsA	NULL
on	NULL
NFAT	NULL
binding	NULL
activity	NULL
is	NULL
mediated	NULL
at	NULL
the	NULL
level	NULL
of	NULL
NFATp-DNA	NULL
interaction	NULL
or	NULL
at	NULL
the	NULL
level	NULL
of	NULL
pro-tein-protein	NULL
interaction	NULL
between	NULL
NFATp	NULL
and	NULL
Fos/Jun	NULL
dimers	NULL
.	NULL

We	NULL
first	NULL
tested	NULL
the	NULL
effect	NULL
of	NULL
CsA	NULL
on	NULL
direct	NULL
DNA	NULL
binding	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

EMSA	NULL
using	NULL
nuclear	NULL
extracts	NULL
from	NULL
unstimulated	NULL
human	NULL
Raji	NULL
B	NULL
cells	NULL
with	NULL
a	NULL
murine	NULL
IL-2	NULL
NFAT	NULL
oligonucleotide	NULL
as	NULL
a	NULL
probe	NULL
showed	NULL
two	NULL
bands	NULL
,	NULL
a	NULL
strong	NULL
lower	NULL
band	NULL
and	NULL
a	NULL
weak	NULL
upper	NULL
band	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

Of	NULL
those	NULL
two	NULL
bands	NULL
,	NULL
however	NULL
,	NULL
only	NULL
the	NULL
strong	NULL
lower	NULL
band	NULL
was	NULL
supershifted	NULL
or	NULL
inhibited	NULL
by	NULL
addition	NULL
of	NULL
antisera	NULL
to	NULL
murine	NULL
NFATp	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
lower	NULL
band	NULL
represents	NULL
a	NULL
NFATpDNA	NULL
complex	NULL
.	NULL

NFATp	NULL
in	NULL
nuclear	NULL
extracts	NULL
of	NULL
CsA-treated	NULL
cells	NULL
lost	NULL
its	NULL
DNA-binding	NULL
activity	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
whereas	NULL
the	NULL
unidentified	NULL
upper	NULL
band	NULL
was	NULL
unaffected	NULL
,	NULL
suggesting	NULL
that	NULL
dephosphorylation	NULL
of	NULL
NFATp	NULL
(	NULL
which	NULL
is	NULL
prevented	NULL
by	NULL
CsA	NULL
)	NULL
is	NULL
required	NULL
for	NULL
DNA-binding	NULL
activity	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
dephosphorylation	NULL
of	NULL
NFAT	NULL
p	NULL
can	NULL
restore	NULL
its	NULL
direct	NULL
DNA-binding	NULL
activity	NULL
,	NULL
nuclear	NULL
extracts	NULL
from	NULL
CsA-treated	NULL
Raji	NULL
B	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
either	NULL
AP	NULL
or	NULL
CaN	NULL
and	NULL
analyzed	NULL
for	NULL
binding	NULL
to	NULL
the	NULL
murine	NULL
IL-2	NULL
NFAT	NULL
motif	NULL
by	NULL
EMSA	NULL
.	NULL

DNA-binding	NULL
activity	NULL
of	NULL
NFATp	NULL
in	NULL
CsA-treated	NULL
cells	NULL
was	NULL
restored	NULL
by	NULL
AP	NULL
and	NULL
CaN	NULL
treatments	NULL
(	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
,	NULL
respec-tively	NULL
)	NULL
,	NULL
and	NULL
the	NULL
restored	NULL
DNA	NULL
binding	NULL
was	NULL
specific	NULL
to	NULL
the	NULL
murine	NULL
NFAT	NULL
motif	NULL
,	NULL
based	NULL
on	NULL
unlabeled	NULL
oligonucleotide	NULL
competition	NULL
and	NULL
supershifts	NULL
with	NULL
antisera	NULL
to	NULL
murine	NULL
NFAT	NULL
p	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Phosphatase	NULL
inhibitors	NULL
blocked	NULL
recovery	NULL
of	NULL
DNA	NULL
binding	NULL
of	NULL
NFATp	NULL
to	NULL
a	NULL
murine	NULL
IL-2	NULL
NFAT	NULL
oligonucleotide	NULL
,	NULL
indicating	NULL
that	NULL
restoration	NULL
resulted	NULL
from	NULL
dephosphorylation	NULL
of	NULL
NFAT	NULL
p	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
.	NULL

The	NULL
NFATp	NULL
:	NULL
DNA	NULL
complex	NULL
restored	NULL
by	NULL
AP	NULL
migrated	NULL
slower	NULL
than	NULL
that	NULL
of	NULL
CsA-untreated	NULL
cells	NULL
,	NULL
while	NULL
the	NULL
complex	NULL
restored	NULL
by	NULL
CaN	NULL
migrated	NULL
at	NULL
a	NULL
position	NULL
identical	NULL
to	NULL
that	NULL
of	NULL
CsA	NULL
untreated	NULL
cells	NULL
.	NULL

Together	NULL
with	NULL
the	NULL
apparent	NULL
molecular	NULL
weight	NULL
differences	NULL
in	NULL
immunoblot	NULL
analyses	NULL
generated	NULL
by	NULL
AP	NULL
and	NULL
CaN	NULL
treatments	NULL
of	NULL
nuclear	NULL
extracts	NULL
(	NULL
Fig	NULL
.	NULL

44	NULL
,	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
,	NULL
this	NULL
indicates	NULL
differing	NULL
degrees	NULL
of	NULL
dephosphorylation	NULL
of	NULL
Mechanism	NULL
for	NULL
Cyclosporin	NULL
A	NULL
Inhibition	NULL
of	NULL
NFAT	NULL
+	NULL
CsA	NULL
=	NULL
[	NULL
7	NULL
<	NULL
+	NULL
ma	NULL
Z	NULL
8	NULL
a.	NULL
s	NULL
-	NULL
oA	NULL
&	NULL
,	NULL
%	NULL
<	NULL
4	NULL
O	NULL
<	NULL
I	NULL
o	NULL
Free	NULL
Probe	NULL
-m	NULL
M	NULL
10	NULL
2	NULL
30	NULL
4	NULL
50	NULL
6	NULL
Fic	NULL
.	NULL

6	NULL
.	NULL

In	NULL
vitro	NULL
dephosphorylation	NULL
of	NULL
human	NULL
NFATp	NULL
restores	NULL
direct	NULL
binding	NULL
to	NULL
the	NULL
murine	NULL
NFAT	NULL
site	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
CsA-treated	NULL
Raji	NULL
cells	NULL
were	NULL
incubated	NULL
either	NULL
alone	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
or	NULL
with	NULL
AP	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
5	NULL
)	NULL
or	NULL
CaN	NULL
(	NULL
lanes	NULL
4	NULL
and	NULL
6	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
phosphatase	NULL
inhibitors	NULL
(	NULL
F	NULL
)	NULL
and	NULL
tested	NULL
for	NULL
DNA-binding	NULL
activity	NULL
to	NULL
a	NULL
murine	NULL
IL-2	NULL
NFAT	NULL
oligonucleotide	NULL
in	NULL
EMSA	NULL
.	NULL

EMSA	NULL
was	NULL
performed	NULL
with	NULL
a	NULL
nuclear	NULL
extract	NULL
from	NULL
CsA-untreated	NULL
Raji	NULL
cells	NULL
for	NULL
comparison	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

Sodium	NULL
pyrophosphate	NULL
(	NULL
20	NULL
mit	NULL
)	NULL
and	NULL
NaF	NULL
(	NULL
50	NULL
mm	NULL
)	NULL
were	NULL
added	NULL
to	NULL
the	NULL
phosphatase	NULL
reaction	NULL
mixtures	NULL
to	NULL
inhibit	NULL
phosphatase	NULL
activity	NULL
of	NULL
AP	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
and	NULL
CaN	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

NFATp-DNA	NULL
complexes	NULL
are	NULL
indicated	NULL
by	NULL
arrows	NULL
.	NULL

NFATp	NULL
and	NULL
suggests	NULL
that	NULL
only	NULL
a	NULL
subset	NULL
of	NULL
phosphorylated	NULL
sites	NULL
is	NULL
involved	NULL
in	NULL
inhibiting	NULL
DNA	NULL
binding	NULL
.	NULL

DISCUSSION	NULL
A	NULL
widely	NULL
accepted	NULL
model	NULL
of	NULL
CsA-mediated	NULL
inhibition	NULL
of	NULL
cytokine	NULL
gene	NULL
expression	NULL
involves	NULL
inactivation	NULL
of	NULL
a	NULL
calcium-depend-ent	NULL
phosphatase	NULL
and	NULL
sequestration	NULL
of	NULL
a	NULL
cytoplasmic	NULL
component	NULL
(	NULL
s	NULL
)	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
NFAT	NULL
.	NULL

It	NULL
has	NULL
been	NULL
suggested	NULL
that	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
,	NULL
a	NULL
cytoplasmic	NULL
component	NULL
(	NULL
s	NULL
)	NULL
is	NULL
dephosphorylated	NULL
by	NULL
the	NULL
Ca**-dependent	NULL
phosphatase	NULL
CaN	NULL
resulting	NULL
in	NULL
its	NULL
translocation	NULL
to	NULL
the	NULL
nucleus	NULL
where	NULL
it	NULL
joins	NULL
Fos/Jun	NULL
proteins	NULL
to	NULL
form	NULL
the	NULL
NFAT	NULL
complex	NULL
(	NULL
Clipstone	NULL
and	NULL
Crabtree	NULL
,	NULL
1992	NULL
;	NULL
McCaffrey	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993a	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
fact	NULL
that	NULL
unstimulated	NULL
human	NULL
Raji	NULL
B	NULL
and	NULL
Jurkat	NULL
T	NULL
cell	NULL
lines	NULL
constitutively	NULL
express	NULL
a	NULL
nuclear	NULL
component	NULL
that	NULL
can	NULL
participate	NULL
in	NULL
reconstitution	NULL
of	NULL
the	NULL
NFAT	NULL
complex	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
Fos/Jun	NULL
heterodimers	NULL
(	NULL
Yaseen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
,	NULL
1994	NULL
)	NULL
poses	NULL
the	NULL
question	NULL
of	NULL
whether	NULL
this	NULL
nuclear	NULL
non-AP-1	NULL
component	NULL
is	NULL
also	NULL
a	NULL
target	NULL
for	NULL
CsA	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
a	NULL
calcium	NULL
signal	NULL
.	NULL

Our	NULL
preliminary	NULL
experiments	NULL
showed	NULL
that	NULL
CsA	NULL
treatment	NULL
of	NULL
unstimulated	NULL
Raji	NULL
and	NULL
Jurkat	NULL
cells	NULL
results	NULL
in	NULL
loss	NULL
of	NULL
reconstitution	NULL
of	NULL
the	NULL
NFAT	NULL
complex	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
Fos/Jun	NULL
heterodimers	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

This	NULL
observation	NULL
can	NULL
not	NULL
be	NULL
accounted	NULL
for	NULL
by	NULL
the	NULL
loss	NULL
of	NULL
stimulation-depend-ent	NULL
translocation	NULL
of	NULL
a	NULL
cytoplasmic	NULL
component	NULL
(	NULL
s	NULL
)	NULL
to	NULL
the	NULL
nucleus	NULL
,	NULL
since	NULL
it	NULL
occurred	NULL
in	NULL
unstimulated	NULL
cells	NULL
in	NULL
which	NULL
the	NULL
factor	NULL
is	NULL
constitutively	NULL
nuclear	NULL
.	NULL

The	NULL
data	NULL
presented	NULL
here	NULL
show	NULL
that	NULL
this	NULL
factor	NULL
is	NULL
a	NULL
human	NULL
homologue	NULL
of	NULL
murine	NULL
NFATp	NULL
and	NULL
point	NULL
to	NULL
an	NULL
additional	NULL
mechanism	NULL
for	NULL
the	NULL
CsA-mediated	NULL
inhibition	NULL
of	NULL
NFAT	NULL
activity	NULL
in	NULL
T	NULL
and	NULL
B	NULL
cells	NULL
.	NULL

Mechanism	NULL
for	NULL
Cyclosporin	NULL
A	NULL
Inhibition	NULL
of	NULL
NFAT	NULL
Several	NULL
lines	NULL
of	NULL
evidence	NULL
suggest	NULL
that	NULL
the	NULL
constitutive	NULL
component	NULL
that	NULL
we	NULL
detect	NULL
in	NULL
nuclear	NULL
extracts	NULL
of	NULL
unstimulated	NULL
B	NULL
and	NULL
T	NULL
cell	NULL
lines	NULL
is	NULL
a	NULL
human	NULL
counterpart	NULL
of	NULL
murine	NULL
NFATp	NULL
.	NULL

1	NULL
)	NULL
Both	NULL
proteins	NULL
are	NULL
able	NULL
to	NULL
reconstitute	NULL
an	NULL
NFAT	NULL
complex	NULL
with	NULL
murine	NULL
and	NULL
human	NULL
IL-2	NULL
NFAT	NULL
binding	NULL
sites	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
Fos/Jun	NULL
heterodimers	NULL
;	NULL
both	NULL
also	NULL
bind	NULL
specifically	NULL
to	NULL
a	NULL
murine	NULL
NFAT	NULL
oligonucleotide	NULL
without	NULL
Fos	NULL
and	NULL
Jun	NULL
proteins	NULL
(	NULL
Jain	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
,	NULL
1993b	NULL
;	NULL
Yaseen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
;	NULL
Figs	NULL
.	NULL

1	NULL
and	NULL
6	NULL
)	NULL
.	NULL

2	NULL
)	NULL
Both	NULL
are	NULL
phosphoproteins	NULL
with	NULL
an	NULL
apparent	NULL
molecular	NULL
mass	NULL
of	NULL
~120	NULL
kDa	NULL
and	NULL
serve	NULL
as	NULL
in	NULL
vitro	NULL
substrates	NULL
of	NULL
CaN	NULL
(	NULL
McCaffrey	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993a	NULL
;	NULL
Figs	NULL
.	NULL

3	NULL
and	NULL
4	NULL
)	NULL
.	NULL

3	NULL
)	NULL
Both	NULL
are	NULL
targets	NULL
of	NULL
CsA	NULL
(	NULL
McCaffrey	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993a	NULL
;	NULL
this	NULL
work	NULL
)	NULL
.	NULL

4	NULL
)	NULL
Antisera	NULL
specific	NULL
to	NULL
the	NULL
murine	NULL
NFATp	NULL
(	NULL
McCaffrey	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993b	NULL
;	NULL
Ho	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
supershift	NULL
NFAT	NULL
complexes	NULL
formed	NULL
by	NULL
the	NULL
human	NULL
constitutive	NULL
component	NULL
on	NULL
both	NULL
human	NULL
and	NULL
murine	NULL
NFAT	NULL
oligonucleotides	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
and	NULL
recognize	NULL
it	NULL
on	NULL
immunoblots	NULL
(	NULL
Figs	NULL
.	NULL

3	NULL
and	NULL
4	NULL
)	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
the	NULL
observation	NULL
that	NULL
an	NULL
NFATp	NULL
homologue	NULL
is	NULL
constitutively	NULL
nuclear	NULL
in	NULL
transformed	NULL
human	NULL
B	NULL
and	NULL
T	NULL
cell	NULL
lines	NULL
is	NULL
intriguing	NULL
as	NULL
NFATp	NULL
is	NULL
mainly	NULL
cytoplasmic	NULL
in	NULL
unstimulated	NULL
murine	NULL
T	NULL
cells	NULL
(	NULL
McCaffrey	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998a	NULL
)	NULL
.	NULL

However	NULL
,	NULL
these	NULL
two	NULL
observations	NULL
are	NULL
not	NULL
mutually	NULL
exclusive	NULL
.	NULL

One	NULL
interpretation	NULL
of	NULL
this	NULL
difference	NULL
is	NULL
that	NULL
transformation-associated	NULL
activation	NULL
in	NULL
Raji	NULL
B	NULL
and	NULL
Jurkat	NULL
T	NULL
cells	NULL
may	NULL
result	NULL
in	NULL
nuclear	NULL
localization	NULL
of	NULL
NFATp	NULL
.	NULL

The	NULL
DNA	NULL
binding	NULL
activity	NULL
of	NULL
nuclear	NULL
NFATp	NULL
in	NULL
unstimulated	NULL
Raji	NULL
and	NULL
Jurkat	NULL
cells	NULL
was	NULL
strongly	NULL
inhibited	NULL
by	NULL
CsA	NULL
treatment	NULL
(	NULL
Figs	NULL
.	NULL

1	NULL
and	NULL
6	NULL
)	NULL
,	NULL
an	NULL
effect	NULL
that	NULL
could	NULL
be	NULL
observed	NULL
within	NULL
the	NULL
first	NULL
hour	NULL
of	NULL
treatment	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
loss	NULL
of	NULL
DNA-binding	NULL
activity	NULL
was	NULL
due	NULL
to	NULL
increased	NULL
phosphorylation	NULL
of	NULL
NFATp	NULL
as	NULL
in	NULL
vitro	NULL
treatment	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
CsA-treated	NULL
cells	NULL
with	NULL
AP	NULL
and	NULL
CaN	NULL
could	NULL
restore	NULL
this	NULL
activity	NULL
(	NULL
Figs	NULL
.	NULL

5	NULL
and	NULL
6	NULL
)	NULL
.	NULL

Increased	NULL
phosphorylation	NULL
of	NULL
NFAT	NULL
p	NULL
appears	NULL
to	NULL
be	NULL
the	NULL
main	NULL
consequence	NULL
of	NULL
CsA-treatment	NULL
in	NULL
Raji	NULL
and	NULL
Jurkat	NULL
cell	NULL
lines	NULL
,	NULL
with	NULL
no	NULL
appreciable	NULL
change	NULL
in	NULL
its	NULL
subcellular	NULL
distribution	NULL
(	NULL
Figs	NULL
.	NULL

3	NULL
and	NULL
4	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
CsA	NULL
not	NULL
only	NULL
inhibits	NULL
the	NULL
translocation	NULL
of	NULL
NFATp	NULL
to	NULL
the	NULL
nucleus	NULL
,	NULL
but	NULL
also	NULL
inhibits	NULL
the	NULL
DNA	NULL
binding	NULL
activity	NULL
of	NULL
NFATp	NULL
that	NULL
is	NULL
already	NULL
in	NULL
the	NULL
nucleus	NULL
.	NULL

These	NULL
observations	NULL
imply	NULL
that	NULL
CsA	NULL
can	NULL
prevent	NULL
NFAT-mediated	NULL
transactivation	NULL
even	NULL
when	NULL
NFATp	NULL
is	NULL
already	NULL
in	NULL
the	NULL
nucleus	NULL
as	NULL
is	NULL
the	NULL
case	NULL
in	NULL
transformed	NULL
cells	NULL
.	NULL

Indeed	NULL
,	NULL
CsA	NULL
can	NULL
inhibit	NULL
NFATp	NULL
DNA	NULL
binding	NULL
activity	NULL
when	NULL
added	NULL
up	NULL
to	NULL
4	NULL
h	NULL
after	NULL
in	NULL
vitro	NULL
cell	NULL
stimulation	NULL
by	NULL
PHA	NULL
and	NULL
PMA	NULL
.	NULL

*	NULL
It	NULL
is	NULL
interesting	NULL
to	NULL
note	NULL
that	NULL
AP	NULL
dephosphorylation	NULL
of	NULL
CsA-treated	NULL
extracts	NULL
resulted	NULL
in	NULL
a	NULL
smaller	NULL
migration	NULL
shift	NULL
on	NULL
a	NULL
SDS-polyacrylamide	NULL
gel	NULL
than	NULL
CaN	NULL
dephosphorylation	NULL
,	NULL
although	NULL
both	NULL
treatments	NULL
resulted	NULL
in	NULL
complete	NULL
restoration	NULL
of	NULL
DNA	NULL
binding	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
NFATp	NULL
from	NULL
Jurkat	NULL
and	NULL
Raji	NULL
cells	NULL
shows	NULL
a	NULL
slight	NULL
difference	NULL
in	NULL
migration	NULL
on	NULL
SDS-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

This	NULL
difference	NULL
is	NULL
reduced	NULL
by	NULL
AP	NULL
treatment	NULL
and	NULL
completely	NULL
abolished	NULL
by	NULL
CaN	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

These	NULL
findings	NULL
suggest	NULL
that	NULL
there	NULL
are	NULL
partially	NULL
dephosphorylated	NULL
forms	NULL
of	NULL
NFATp	NULL
in	NULL
Raji	NULL
and	NULL
Jurkat	NULL
cells	NULL
,	NULL
and	NULL
this	NULL
dephosphorylation	NULL
may	NULL
involve	NULL
CaN	NULL
or	NULL
other	NULL
phosphatases	NULL
.	NULL

Indeed	NULL
,	NULL
treatment	NULL
of	NULL
Jurkat	NULL
cells	NULL
with	NULL
ionomycin	NULL
led	NULL
to	NULL
further	NULL
dephosphorylation	NULL
of	NULL
NFATp	NULL
,	NULL
which	NULL
may	NULL
be	NULL
necessary	NULL
for	NULL
transcriptional	NULL
activation	NULL
but	NULL
not	NULL
for	NULL
DNA-bind-ing	NULL
.	NULL
``	NULL

Consequently	NULL
,	NULL
NFATp	NULL
may	NULL
have	NULL
multiple	NULL
phosphorylation	NULL
sites	NULL
,	NULL
only	NULL
some	NULL
of	NULL
which	NULL
are	NULL
involved	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
DNA-binding	NULL
activity	NULL
,	NULL
while	NULL
others	NULL
may	NULL
subserve	NULL
different	NULL
functions	NULL
such	NULL
as	NULL
transcriptional	NULL
activation	NULL
and	NULL
subcellular	NULL
localization	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
our	NULL
findings	NULL
demonstrate	NULL
that	NULL
immunosuppressive	NULL
drugs	NULL
can	NULL
inhibit	NULL
the	NULL
activation	NULL
of	NULL
NFAT	NULL
by	NULL
directly	NULL
preventing	NULL
the	NULL
DNA	NULL
binding	NULL
ability	NULL
of	NULL
NFATp	NULL
through	NULL
increased	NULL
phosphorylation	NULL
,	NULL
suggesting	NULL
that	NULL
these	NULL
drugs	NULL
can	NULL
affect	NULL
NFAT	NULL
function	NULL
at	NULL
multiple	NULL
steps	NULL
.	NULL

Our	NULL
data	NULL
also	NULL
suggest	NULL
the	NULL
presence	NULL
of	NULL
multiple	NULL
physiologically	NULL
important	NULL
phosphorylation	NULL
sites	NULL
*	NULL
J	NULL
.	NULL

Park	NULL
and	NULL
S.	NULL
Sharma	NULL
,	NULL
unpublished	NULL
data	NULL
.	NULL

20659	NULL
within	NULL
the	NULL
NFAT	NULL
molecule	NULL
and	NULL
raise	NULL
the	NULL
question	NULL
of	NULL
whether	NULL
CaN	NULL
is	NULL
the	NULL
only	NULL
phosphatase	NULL
involved	NULL
in	NULL
NFAT	NULL
regulation	NULL
and	NULL
in	NULL
the	NULL
response	NULL
to	NULL
CsA	NULL
and	NULL
FK-506	NULL
.	NULL

Acknowledgments-We	NULL
thank	NULL
Dr.	NULL
Abby	NULL
Maizel	NULL
for	NULL
thoughtful	NULL
reading	NULL
of	NULL
the	NULL
manuscript	NULL
;	NULL
Dr.	NULL
Peter	NULL
Shank	NULL
for	NULL
providing	NULL
HeLa	NULL
cell	NULL
line	NULL
;	NULL
and	NULL
Drs	NULL
.	NULL

Tom	NULL
Curran	NULL
and	NULL
Tom	NULL
Kerppola	NULL
for	NULL
providing	NULL
recombinant	NULL
Fos	NULL
and	NULL
Jun	NULL
proteins	NULL
and	NULL
for	NULL
valuable	NULL
suggestions	NULL
and	NULL
criticisms	NULL
.	NULL

We	NULL
also	NULL
thank	NULL
Drs	NULL
.	NULL

Jugnu	NULL
Jain	NULL
and	NULL
Akiko	NULL
Takeda	NULL
for	NULL
helpful	NULL
advice	NULL
and	NULL
discussion	NULL
on	NULL
various	NULL
aspects	NULL
of	NULL
this	NULL
work	NULL
.	NULL

REFERENCES	NULL
Bierer	NULL
,	NULL
B.	NULL
E.	NULL
,	NULL
Hollander	NULL
,	NULL
G.	NULL
,	NULL
Fruman	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Burakoff	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
Curr	NULL
.	NULL

Opin	NULL
.	NULL

Immunol	NULL
.	NULL

5	NULL
,	NULL
163-773	NULL
Boise	NULL
,	NULL
L.	NULL
H.	NULL
,	NULL
Petryniak	NULL
,	NULL
B.	NULL
,	NULL
Mao	NULL
,	NULL
X.	NULL
,	NULL
June	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
Wang	NULL
,	NULL
C.-Y	NULL
.	NULL

,	NULL
Lindsten	NULL
,	NULL
T.	NULL
,	NULL
Bravo	NULL
,	NULL
R.	NULL
,	NULL
Kovary	NULL
,	NULL
K.	NULL
,	NULL
Leiden	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
and	NULL
Thompson	NULL
,	NULL
C.	NULL
B	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13	NULL
,	NULL
1911-1919	NULL
Cahn	NULL
,	NULL
R.	NULL
D.	NULL
,	NULL
Kaplan	NULL
,	NULL
N.	NULL
O.	NULL
,	NULL
Levine	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Zwilling	NULL
,	NULL
E.	NULL
(	NULL
1962	NULL
)	NULL
Science	NULL
136	NULL
,	NULL
962-969	NULL
Choi	NULL
,	NULL
M.	NULL
S.	NULL
,	NULL
Brines	NULL
,	NULL
R.	NULL
D.	NULL
,	NULL
Holman	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
and	NULL
Klaus	NULL
,	NULL
G.	NULL
G.	NULL
B	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Immunity	NULL
1	NULL
,	NULL
179-187	NULL
Chuypilo	NULL
,	NULL
S.	NULL
,	NULL
Schomberg	NULL
,	NULL
C.	NULL
,	NULL
Gerwig	NULL
,	NULL
R.	NULL
,	NULL
Heinfling	NULL
,	NULL
A.	NULL
,	NULL
Reeves	NULL
,	NULL
R.	NULL
,	NULL
Grumit	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
Serfling	NULL
,	NULL
E.	NULL
(	NULL
1998	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

21	NULL
,	NULL
5694-5704	NULL
Clipstone	NULL
,	NULL
N.	NULL
A.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1992	NULL
)	NULL
Nature	NULL
357	NULL
,	NULL
695-697	NULL
Cockerill	NULL
,	NULL
P.	NULL
N.	NULL
,	NULL
Shannon	NULL
,	NULL
F.	NULL
,	NULL
Bert	NULL
,	NULL
A.	NULL
G.	NULL
,	NULL
Ryan	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
and	NULL
Vadas	NULL
,	NULL
M.	NULL
A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

90	NULL
,	NULL
2466-2470	NULL
Durand	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
Shaw	NULL
,	NULL
J.-P.	NULL
,	NULL
Bush	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Replogle	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
Belagaje	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1988	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

8	NULL
,	NULL
1715-1724	NULL
Emmel	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
Verweij	NULL
,	NULL
C.	NULL
L.	NULL
,	NULL
Durand	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
Higgins	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
Lacy	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1989	NULL
)	NULL
Science	NULL
246	NULL
,	NULL
1617-1620	NULL
Flanagan	NULL
,	NULL
W.	NULL
M.	NULL
,	NULL
Corthésy	NULL
,	NULL
B.	NULL
,	NULL
Bram	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1991	NULL
)	NULL
Nature	NULL
852	NULL
,	NULL
803-807	NULL
Goldfeld	NULL
,	NULL
A.	NULL
E.	NULL
,	NULL
McCaffrey	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
Strominger	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
and	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

178	NULL
,	NULL
1365-1379	NULL
Goldfeld	NULL
,	NULL
A.	NULL
E.	NULL
,	NULL
Tsai	NULL
,	NULL
E.	NULL
,	NULL
Kincaid	NULL
,	NULL
R.	NULL
,	NULL
Belshaw	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
Schreiber	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
Strominger	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
and	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

180	NULL
,	NULL
763-768	NULL
Granelli-Piperno	NULL
,	NULL
A.	NULL
,	NULL
Nolan	NULL
,	NULL
P.	NULL
,	NULL
Inaba	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Steinman	NULL
,	NULL
R.	NULL
M.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

172	NULL
,	NULL
1869-1872	NULL
Ho	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
Jain	NULL
,	NULL
J.	NULL
,	NULL
Rao	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Hogan	NULL
,	NULL
P.	NULL
G.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269	NULL
,	NULL
28181-28186	NULL
Jain	NULL
,	NULL
J.	NULL
,	NULL
McCaffrey	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
Valge-Archer	NULL
,	NULL
V.	NULL
E.	NULL
,	NULL
and	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Nature	NULL
356	NULL
,	NULL
801-804	NULL
Jain	NULL
,	NULL
J.	NULL
,	NULL
McCaffrey	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
Miner	NULL
,	NULL
Z.	NULL
,	NULL
Kerppola	NULL
,	NULL
T.	NULL
K.	NULL
,	NULL
Lambert	NULL
,	NULL
J.	NULL
N.	NULL
,	NULL
Verdine	NULL
,	NULL
G.	NULL
L.	NULL
,	NULL
Curran	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1998a	NULL
)	NULL
Nature	NULL
365	NULL
,	NULL
852-355	NULL
Jain	NULL
,	NULL
J.	NULL
,	NULL
Miner	NULL
,	NULL
Z.	NULL
,	NULL
and	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1993b	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

151	NULL
,	NULL
837-848	NULL
Jain	NULL
,	NULL
J.	NULL
,	NULL
Nalefski	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
McCaffrey	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
Johnson	NULL
,	NULL
R.	NULL
S.	NULL
,	NULL
Spiegelman	NULL
,	NULL
B.	NULL
M.	NULL
,	NULL
Papaioannou	NULL
,	NULL
V.	NULL
,	NULL
and	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14	NULL
,	NULL
1566-1574	NULL
Kerppola	NULL
,	NULL
T.	NULL
K.	NULL
,	NULL
and	NULL
Curran	NULL
,	NULL
T.	NULL
(	NULL
1991	NULL
)	NULL
Cell	NULL
66	NULL
,	NULL
317-326	NULL
Masuda	NULL
,	NULL
E.	NULL
S.	NULL
,	NULL
Tokumitsu	NULL
,	NULL
H.	NULL
,	NULL
Tsuboi	NULL
,	NULL
A.	NULL
,	NULL
Shlomai	NULL
,	NULL
J.	NULL
,	NULL
Hung	NULL
,	NULL
P.	NULL
,	NULL
Arai	NULL
,	NULL
K.-L.	NULL
,	NULL
and	NULL
Arai	NULL
,	NULL
N.	NULL
(	NULL
1993	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18	NULL
,	NULL
7399-7407	NULL
Mattila	NULL
,	NULL
P.	NULL
S.	NULL
,	NULL
Ullman	NULL
,	NULL
K.	NULL
S.	NULL
,	NULL
Fiering	NULL
,	NULL
S.	NULL
,	NULL
Emmel	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
McCutcheon	NULL
,	NULL
M.	NULL
,	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
and	NULL
Herzenberg	NULL
,	NULL
L.	NULL
A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

9	NULL
,	NULL
4425-4483	NULL
McCaffrey	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
Perrino	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
,	NULL
Soderling	NULL
,	NULL
T.	NULL
R.	NULL
,	NULL
and	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
19988	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268	NULL
,	NULL
3747-3752	NULL
McCaffrey	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
Luo	NULL
,	NULL
C.	NULL
,	NULL
Kerppola	NULL
,	NULL
T.	NULL
K.	NULL
,	NULL
Jain	NULL
,	NULL
J.	NULL
,	NULL
Badalian	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
Ho	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
Burgeon	NULL
,	NULL
E.	NULL
,	NULL
Lane	NULL
,	NULL
W.	NULL
S.	NULL
,	NULL
Lambert	NULL
,	NULL
J.	NULL
N.	NULL
,	NULL
Curran	NULL
,	NULL
T.	NULL
,	NULL
Verdine	NULL
,	NULL
G.	NULL
L.	NULL
,	NULL
Rao	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Hogan	NULL
,	NULL
P.	NULL
G.	NULL
(	NULL
1993b	NULL
)	NULL
Science	NULL
262	NULL
,	NULL
750-754	NULL
Northrop	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Ullman	NULL
,	NULL
K.	NULL
S.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1993	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268	NULL
,	NULL
2917-2923	NULL
Northrop	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Ho	NULL
,	NULL
S.	NULL
N.	NULL
,	NULL
Chen	NULL
,	NULL
L.	NULL
,	NULL
Thomas	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Timmerman	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
Nolan	NULL
,	NULL
G.	NULL
P.	NULL
,	NULL
Admon	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1994	NULL
)	NULL
Nature	NULL
8369	NULL
,	NULL
497-502	NULL
O'Keefe	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
Tamura	NULL
,	NULL
J.	NULL
,	NULL
Kincaid	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
Toceci	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
and	NULL
O'Neill	NULL
,	NULL
E.	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Nature	NULL
357	NULL
,	NULL
692-694	NULL
Pognonesc	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Roeder	NULL
,	NULL
R.	NULL
G.	NULL
(	NULL
1991	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

11	NULL
,	NULL
5125-5136	NULL
Randak	NULL
,	NULL
C.	NULL
,	NULL
Brabletz	NULL
,	NULL
T.	NULL
,	NULL
Hergenrother	NULL
,	NULL
M.	NULL
,	NULL
Sobotta	NULL
,	NULL
I.	NULL
,	NULL
and	NULL
Serfling	NULL
,	NULL
E.	NULL
(	NULL
1990	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

9	NULL
,	NULL
2529-2536	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
15	NULL
,	NULL
274-281	NULL
Rooney	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
Hodge	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
McCaffrey	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
Rao	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Glimcher	NULL
,	NULL
L.	NULL
H.	NULL
(	NULL
1994	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

13	NULL
,	NULL
625-633	NULL
Sawadogo	NULL
,	NULL
M.	NULL
,	NULL
Van	NULL
Dyke	NULL
,	NULL
M.	NULL
W.	NULL
,	NULL
Gregor	NULL
,	NULL
P.	NULL
D.	NULL
,	NULL
and	NULL
Roeder	NULL
,	NULL
R.	NULL
G.	NULL
(	NULL
1988	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

263	NULL
,	NULL
11985-11993	NULL
Schreiber	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1992	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
18	NULL
,	NULL
136-142	NULL
Sen	NULL
,	NULL
J.	NULL
,	NULL
Shinkai	NULL
,	NULL
Y.	NULL
,	NULL
Alt	NULL
,	NULL
F.	NULL
W.	NULL
,	NULL
Sen	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Burakoff	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

180	NULL
,	NULL
2321-2327	NULL
Shaw	NULL
,	NULL
J.-P.	NULL
,	NULL
Utz	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
Durand	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
Toole	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
Emmel	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1988	NULL
)	NULL
Science	NULL
241	NULL
,	NULL
202-205	NULL
Sigal	NULL
,	NULL
N.	NULL
H.	NULL
,	NULL
and	NULL
Dumont	NULL
,	NULL
F.	NULL
J	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

10	NULL
,	NULL
519-560	NULL
Szabo	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
Gold	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
Murphy	NULL
,	NULL
T.	NULL
L.	NULL
,	NULL
and	NULL
Murphy	NULL
,	NULL
K.	NULL
M.	NULL
(	NULL
1993	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18	NULL
,	NULL
4793-4805	NULL
Tsuboi	NULL
,	NULL
A.	NULL
,	NULL
Masuda	NULL
,	NULL
E.	NULL
S.	NULL
,	NULL
Naito	NULL
,	NULL
Y.	NULL
,	NULL
Tokumitsu	NULL
,	NULL
H.	NULL
,	NULL
Arai	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Arai	NULL
,	NULL
N.	NULL
(	NULL
1994	NULL
)	NULL
Mol	NULL
.	NULL

Biol	NULL
.	NULL

Cell	NULL
5	NULL
,	NULL
119-128	NULL
Ullman	NULL
,	NULL
K.	NULL
S.	NULL
,	NULL
Northrop	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Verweij	NULL
,	NULL
C.	NULL
L.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1990	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
,	NULL
8	NULL
,	NULL
421-452	NULL
Venkataraman	NULL
,	NULL
L.	NULL
,	NULL
Francis	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
Wang	NULL
,	NULL
Z.	NULL
,	NULL
Liu	NULL
,	NULL
J.	NULL
,	NULL
Rothstein	NULL
,	NULL
T.	NULL
L.	NULL
,	NULL
and	NULL
Sen	NULL
,	NULL
R.	NULL
(	NULL
1994	NULL
)	NULL
Immunity	NULL
1	NULL
,	NULL
189-196	NULL
Wang	NULL
,	NULL
D.	NULL
Z.	NULL
,	NULL
McCaffrey	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
and	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Ann	NULL
.	NULL

N.	NULL
Y.	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

,	NULL
in	NULL
press	NULL
Yaseen	NULL
,	NULL
N.	NULL
R.	NULL
,	NULL
Maizel	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
Wang	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
Sharma	NULL
,	NULL
S.	NULL
(	NULL
1998	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268	NULL
,	NULL
14285-14293	NULL
Yaseen	NULL
,	NULL
N.	NULL
R.	NULL
,	NULL
Park	NULL
,	NULL
J.	NULL
,	NULL
Kerppola	NULL
,	NULL
T.	NULL
,	NULL
Curran	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Sharma	NULL
,	NULL
S.	NULL
(	NULL
1994	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14	NULL
,	NULL
6886-6895	NULL

